Category: Blog

HealthEvidenceDigest offers evidence based coverage of FDA approvals, regulatory updates, clinical research, and drug safety communications. Posts focus on the data behind each decision and explain the potential impact on patient care and clinical practice.

Younger Endometrial Cancer Survivors Face Years of Unnecessary Suffering. New Evidence Says One Treatment Has Been Wrongly Withheld.

The essentials: A study published in Menopause, the journal of The Menopause Society, on March 4, 2026 analyzed data from more than 2,800 women aged 18 to 51 with endometrial cancer across 68 U.S. healthcare organizations. The key finding: local, low-dose vaginal estrogen therapy was not associated with elevated risk of endometrial cancer recurrence compared to women who did not use it. Only 5.6% of eligible women in the dataset had initiated vaginal estrogen therapy, despite its documented benefits for genitourinary symptoms of menopause. This is the largest known U.S. study to examine this specific question. The study population: women aged 18 to 51, meaning younger survivors experiencing treatment-induced early menopause. Mean treatment duration in the vaginal ET group: 1.88 years. Important context: the FDA removed the boxed warning from low-dose vaginal estrogen products in 2023, a regulatory change that preceded this study and that this data now supports clinically.

There is a specific kind of suffering that is common enough to have a clinical name but uncommon enough that it tends to fall through the cracks of oncology care. Women who survive endometrial cancer at younger ages, typically through hysterectomy that removes both ovaries, experience sudden, complete estrogen loss. Not the gradual perimenopausal transition that most women navigate. Abrupt menopause, overnight, in their 30s or 40s.

The symptoms can be severe. Genitourinary syndrome of menopause (GSM), the clinical term for the collection of vaginal, vulvar, and urinary symptoms caused by estrogen deficiency, does not improve on its own. Vaginal tissue atrophies. Intercourse becomes painful or impossible. Urinary urgency, frequency, and recurrent infections become chronic. Hot flashes disrupt sleep. And the women dealing with all of this are often told they cannot use estrogen because they have had a hormone-sensitive cancer.

A study published in Menopause on March 4, 2026 is the largest U.S. analysis to date addressing whether that restriction is justified for low-dose vaginal estrogen specifically. The finding is reassuring: among younger survivors of endometrial cancer who used local, low-dose vaginal estrogen therapy, the risk of cancer recurrence was not elevated compared to survivors who did not use it.

Endometrial Cancer in Younger Women: The Problem This Study Is Addressing

Endometrial cancer is the most common gynecologic malignancy in the United States, with approximately 67,000 new diagnoses annually. It is predominantly a postmenopausal disease, but incidence in younger women has been rising steadily. The press release accompanying this study cited an increase in early-onset endometrial cancer from 2.2 to 3.3 per 100,000 women in those aged 50 and younger between 2000 and 2019 in the United States. That is a 50% increase in incidence over two decades in a population that was previously considered relatively low-risk.

The reasons for the increase are not fully established, but the association with obesity and metabolic syndrome is well documented. Excess adipose tissue converts androgen precursors to estrone, producing chronically elevated estrogen levels without the counterbalancing effect of progesterone, which is the endometrial carcinogen driving most endometrioid-type endometrial cancers.

Most early-stage endometrial cancers are treated with hysterectomy, often including bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes). For premenopausal women, oophorectomy causes immediate surgical menopause. Some patients also receive radiation therapy or chemotherapy, which can further damage ovarian function and exacerbate menopausal symptoms.

The result is that a woman who is 38, or 44, or 50, who has just finished cancer treatment and is in remission, may be experiencing menopausal symptoms that are more severe than what most women in natural menopause experience, with fewer treatment options available because of the cancer history.

Why Vaginal Estrogen Has Been Avoided — and Why That May Be Changing

The reluctance to prescribe estrogen of any kind to endometrial cancer survivors is rooted in a legitimate biological concern. Most endometrial cancers are estrogen-receptor positive, meaning estrogen exposure is implicated in their development. The standard thinking has been that restoring any estrogen after treatment might stimulate residual or occult cancer cells.

That concern has been compounded for years by labeling: until 2023, all estrogen-containing products, including low-dose vaginal formulations, carried an FDA boxed warning stating risks that were established from studies of systemic, higher-dose hormonal therapy. The warning did not differentiate between oral estrogen pills taken systemically and a small estradiol tablet inserted vaginally, even though the pharmacokinetics are fundamentally different.

Low-dose vaginal estrogen products work locally. A vaginal estradiol tablet or ring at the lowest available doses produces serum estradiol levels that remain within the normal postmenopausal range, because the product is absorbed primarily through vaginal tissue to act locally, with minimal systemic absorption. This is pharmacologically distinct from swallowing an estrogen pill that circulates throughout the body.

In 2023, the FDA recognized this distinction and removed the boxed warning from low-dose vaginal estrogen products, updating their labeling to reflect that the systemic exposure and associated risks documented for systemic hormone therapy do not apply to these preparations. The clinical study published in March 2026 now provides real-world evidence supporting that regulatory decision specifically in the context of endometrial cancer survivors.

The Study: Design, Population, and Results

The study, published in the March 2026 issue of Menopause, drew on electronic health records and insurance claims data from 68 healthcare organizations across the United States. Researchers identified women aged 18 to 51 who had been diagnosed with endometrial cancer.

From that dataset of more than 2,800 women, they created a matched cohort design: 1,412 survivors who had initiated local, low-dose vaginal estrogen therapy were matched 1:1 with 1,412 survivors who had not used it. The matching approach controls for confounding by ensuring the two groups were comparable in relevant baseline characteristics.

The mean duration of vaginal ET use in the treatment group was 1.88 years. This is important context that the original stub post did not provide: nearly two years of use, not a brief test course. That duration makes the non-elevated recurrence finding more clinically meaningful, because it addresses the question of sustained exposure rather than just initial use.

Primary finding	Vaginal ET use was not associated with elevated risk of endometrial cancer recurrence compared to matched non-users
Matched cohort size	1,412 ET users matched 1:1 with 1,412 non-users
Overall study population	More than 2,800 women aged 18 to 51 with endometrial cancer across 68 U.S. healthcare organizations
Mean treatment duration	1.88 years
Vaginal ET initiation rate	Only 5.6% of eligible younger survivors
Study scope	Largest known U.S. analysis of endometrial cancer recurrence with local, low-dose vaginal ET in this population

Source: Vaginal estrogen therapy utilization and associated outcomes in younger survivors of endometrial cancer. Menopause. March 4, 2026.

The 5.6% initiation rate is the second major finding and arguably the more actionable one. If only about 1 in 18 eligible younger survivors is using a therapy that the evidence now suggests is safe and that addresses symptoms the press release describes as rarely improving without treatment, there is a large gap between what the data supports and what is happening in clinical practice.

What the Study Does and Doesn’t Tell Us

The finding is reassuring, but several limitations are worth understanding before interpreting it as a definitive clearance for vaginal estrogen in all endometrial cancer survivors.

Study design limitations: This is a retrospective cohort study using electronic health records and insurance claims data, not a randomized controlled trial. Matched cohort designs control for measured confounders, but unmeasured confounding is always possible. Women who received vaginal ET may have had systematically different disease characteristics, follow-up patterns, or oncologist preferences than those who did not, even after matching.

Short-term follow-up: A mean treatment duration of 1.88 years is meaningful but may not capture recurrence events that occur at later timepoints. Endometrial cancer recurrence can happen years after treatment, and longer-term follow-up data from this population would be valuable.

Histologic heterogeneity: Endometrial cancers are not all the same. Endometrioid adenocarcinoma (Type I), the most common subtype, is strongly estrogen-driven. Type II tumors, including serous, clear cell, and carcinosarcoma, are not estrogen-driven in the same way and carry a worse prognosis. The press release does not report subtype-specific recurrence rates, and understanding whether the safety finding holds equally across all subtypes matters for individual patient counseling.

Stage distribution: Similarly, the study’s population spans early and potentially more advanced stages. Whether the non-elevated recurrence finding holds for women with higher-stage disease at diagnosis is not fully reported in the press release summary.

These limitations do not undermine the study’s value. They are the normal caveats that attend any real-world evidence study in a rare clinical situation where a randomized trial is not feasible. The appropriate interpretation is that the largest available U.S. evidence base is reassuring, not that the question is fully settled.

How vaginal estrogen is different from systemic hormone therapy: the pharmacokinetics that matter Systemic hormone therapy, whether oral tablets, transdermal patches, or injectable formulations, is absorbed into the bloodstream and distributes estrogen throughout the body. This systemic exposure is what drives the risks of blood clots, breast cancer, and cardiovascular events documented in studies like the Women’s Health Initiative. Low-dose vaginal estrogen works differently. Products such as low-dose vaginal estradiol tablets (e.g., Vagifem), estradiol vaginal rings at the lowest dose (Estring), and vaginal cream at low doses act primarily on the local vaginal tissue. Studies measuring serum estradiol levels in postmenopausal women using these products have found that systemic absorption is minimal, with levels remaining in the normal postmenopausal range rather than rising to premenopausal levels. This pharmacokinetic difference is the basis for the FDA’s 2023 decision to remove the systemic HT boxed warning from these products, and it is the biological rationale for why vaginal estrogen may be safer in cancer survivors than systemic formulations.

What This Means for Younger Survivors of Endometrial Cancer

Genitourinary syndrome of menopause (GSM) includes vaginal dryness, vaginal atrophy, pain during intercourse (dyspareunia), urinary urgency, frequency, and recurrent urinary tract infections. It is one of the most bothersome and least discussed consequences of cancer treatment in younger women, and unlike hot flashes, which tend to diminish over time for many women, GSM does not improve without treatment. It often worsens.

The nonhormone options for GSM, including vaginal moisturizers, lubricants, and in some cases ospemifene (an oral selective estrogen receptor modulator for dyspareunia), provide partial relief for some women but not the tissue restoration that estrogen produces. Laser and radiofrequency-based treatments for vaginal atrophy are also available but lack the long-term evidence base of vaginal estrogen.

Dr. Monica Christmas, associate medical director for The Menopause Society, noted in the study commentary that genitourinary symptoms associated with menopause rarely improve without treatment and are exacerbated in the context of abrupt, early menopause. She emphasized that helping survivors of endometrial cancer make evidence-based decisions about their care is empowering, especially during a vulnerable time, and that expanding treatment options to include local, low-dose vaginal estrogen will have long-lasting benefits for this population.

If you are a younger survivor of endometrial cancer experiencing genitourinary symptoms, here is what the current evidence supports:

Vaginal estrogen has now been studied in this specific population. This is no longer an area with no data. The largest U.S. study to examine this question found no elevated recurrence risk with mean nearly two-year use.

The conversation with your oncologist is evidence-based now. If you have been told vaginal estrogen is off-limits because of your cancer history, this study is directly relevant to that conversation. The appropriate clinical decision involves your specific cancer type, stage, time since treatment, and current health status, but the blanket restriction is increasingly unsupported by the available evidence.

The FDA removed the boxed warning in 2023. This regulatory change means low-dose vaginal estrogen no longer carries the same warning label as systemic hormone therapy. Your pharmacist or prescriber may not have updated you on this.

Initiation rates are low, but they should not be. Only 5.6% of eligible younger survivors in this large dataset had used vaginal estrogen. That number is likely a reflection of the fear and misinformation that this and future studies are meant to address.

What to ask your care team: Whether local, low-dose vaginal estrogen is appropriate for your specific cancer type and stage; which formulation (tablet, ring, or cream) is appropriate; what monitoring is reasonable during use; and whether referral to a gynecologic oncologist or menopause specialist is indicated for this conversation.

The Menopause Society’s practitioner finder can help locate clinicians with menopause medicine certification who are familiar with hormone therapy decisions in cancer survivors. The Society of Gynecologic Oncology is the primary professional organization for gynecologic cancer specialists and maintains patient resources on endometrial cancer survivorship.

This study is part of a broader shift in women’s health toward evidence-based approaches that address the full consequences of cancer treatment rather than simply managing the tumor. For related coverage, see our posts on the first approved immunotherapy for ovarian cancer, hormone therapy underuse in women with premature ovarian insufficiency, and the first non-hormonal endometriosis drug entering human trials.

Sources

Primary study: Vaginal estrogen therapy utilization and associated outcomes in younger survivors of endometrial cancer. Menopause. March 4, 2026.

The Menopause Society press release: Vaginal Estrogen Therapy Not Linked to Cancer Recurrence in Survivors of Endometrial Cancer. menopause.org. March 4, 2026.

FDA boxed warning removal: FDA Removes Boxed Warning from Low-Dose Vaginal Estrogen Products. FDA.gov. 2023.

Endometrial cancer overview: Uterine Cancer. National Cancer Institute.

Endometrial cancer and estrogen receptor biology: Endometrial Cancer: Molecular Subtypes and Hormonal Sensitivity. PMC7698737.

Genitourinary syndrome of menopause: Genitourinary Syndrome of Menopause: An Overview of Clinical Manifestations, Pathophysiology, Etiology, Evaluation, and Management. PMC7349626.

ACOG hysterectomy resource: Hysterectomy: FAQs. American College of Obstetricians and Gynecologists.

Obesity and endometrial cancer: Obesity and Cancer. National Cancer Institute.

Metabolic syndrome overview: Metabolic Syndrome. StatPearls. NCBI.

Ospemifene FDA approval: FDA approves ospemifene for vaginal dryness and pain during sex due to menopause. FDA.gov.

Menopause Society practitioner finder: Find a Menopause Healthcare Practitioner.

Patient resources: The Menopause Society | Society of Gynecologic Oncology | American Cancer Society: Endometrial Cancer | National Cancer Institute: Uterine Cancer

Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about hormone therapy use in endometrial cancer survivors should be made in consultation with a gynecologic oncologist and/or a clinician experienced in menopause medicine, taking into account individual cancer type, stage, treatment history, and current health status.

April 19, 2026

The FDA Just Removed the Age Limit on Needle-Free Epinephrine. Here Is What Families and Caregivers Need to Know.

The essentials: On March 27, 2026, the FDA approved a label update for neffy 1 mg (epinephrine nasal spray, ARS Pharmaceuticals) removing the minimum age requirement from the indication. Any patient weighing 33 pounds (15 kg) or more can now use neffy 1 mg for emergency treatment of Type I allergic reactions, including anaphylaxis, regardless of age. Previously, the 1 mg dose required patients to be at least 4 years old AND weigh between 33 and 66 pounds. The age floor is now gone entirely. Who this affects: approximately 25% of patients in the 33 to 66 pound weight range are under age 4, a group that was previously excluded despite meeting the weight criterion and facing real anaphylaxis risk. The label update also clarified: sniffing after administration is not required for the drug to work; the device remains usable if accidentally frozen and thawed; high-temperature exposure up to 122°F for brief periods does not compromise the product. What neffy is: a needle-free intranasal epinephrine spray that delivers epinephrine through the nasal mucosa without injection, cleared as the first non-injectable epinephrine option for anaphylaxis. Available in two doses: neffy 1 mg for patients 33 to 66 pounds (15 to 30 kg) and neffy 2 mg for patients 66 pounds or more (30 kg or more).

Anaphylaxis is a medical emergency. It can progress from first symptoms to respiratory failure or cardiovascular collapse within minutes. The only FDA-approved first-line treatment is epinephrine, and the evidence is unambiguous: early administration saves lives. Delayed administration of epinephrine is a consistent factor in anaphylaxis fatalities.

Yet epinephrine is frequently not given when it should be, and the reason is often not the absence of a device. It is fear of the needle.

Multiple studies have documented that a significant proportion of caregivers, parents, and even patients delay or avoid using epinephrine autoinjectors because of needle phobia, fear of injuring the child or themselves during a high-stress emergency, or hesitation about whether the situation truly warrants injection. One survey found that fewer than half of patients at risk for anaphylaxis consistently carry their epinephrine, and non-adherence is frequently attributed to the injection format itself.

neffy (epinephrine nasal spray) was developed specifically to address this barrier. It delivers epinephrine through the nasal mucosa without a needle. It is compact, discreet, and does not require injection technique. The March 27, 2026 label update makes it accessible to the youngest weight-eligible patients for the first time.

What Changed and Why It Matters

The original neffy 1 mg approval in May 2025 included a pediatric age restriction: patients using the 1 mg dose had to be at least 4 years old in addition to meeting the 33 to 66 pound weight criterion. Children under 4 who were in the eligible weight range were excluded from the labeled indication.

The updated label removes the age floor entirely. Eligibility is now determined solely by weight: 33 pounds or more for the 1 mg dose, regardless of how old the patient is.

This is not a small gap. Approximately 25% of patients in the 33 to 66 pound weight range are under 4 years of age. Anaphylaxis in young children is not rare. Food allergies affect approximately 8% of children, and the foods most commonly causing severe reactions in young children, including peanuts, tree nuts, milk, and egg, are foods that toddlers and preschool-aged children routinely encounter. A 3-year-old who weighs 35 pounds and has a severe peanut allergy was previously outside the labeled indication for neffy despite being in the labeled weight range. That gap is now closed.

The Clinical Evidence Behind the Label Expansion

The age requirement was removed based on clinical data presented to the FDA, including pharmacokinetic and pharmacodynamic evidence. Here is what the data shows.

Pharmacokinetic equivalence to injectable epinephrine

The original approval of neffy 1 mg was based on extensive clinical trials demonstrating that pharmacokinetic and pharmacodynamic responses in pediatric and adult subjects were consistent with those of injectable epinephrine products. This means neffy delivers comparable blood concentrations of epinephrine and produces comparable effects on blood pressure and heart rate as intramuscular autoinjector products.

This is the pharmacological foundation of the entire neffy program: if the blood epinephrine levels achieved are equivalent, the clinical effect should be equivalent. That equivalence was established in healthy adults and pediatric subjects in the original approval.

Real-world effectiveness data

Since neffy’s approval, real-world prescribing data has been accumulating. Real-world data show that a single dose of neffy achieves an 89.2% symptom resolution rate in anaphylaxis, comparable to the 88.9% rate observed with intramuscular epinephrine autoinjectors. That near-identical real-world effectiveness rate across the two delivery formats is a meaningful data point for families deciding between options.

Pediatric trial response data

In pediatric clinical trials, 100% of patients responded to a single dose of neffy, with a median response time of 16 minutes. Adverse events in pediatric trials were generally mild and transient, consistent with the known epinephrine side effect profile (increased heart rate, pallor, tremor) rather than drug-specific adverse effects from the nasal route.

Human factors studies

Human factors studies demonstrated that children as young as 10 years old can use neffy effectively by following the instructions, and that untrained individuals, including babysitters, teachers, and other non-medical caregivers, can successfully administer the device in simulated emergency conditions. This real-world usability finding is as important as the pharmacokinetic data for a rescue medication whose effectiveness depends on whether it actually gets used.

The Other Label Updates: Storage and Administration Clarifications

The March 27 label update also includes several practical clarifications that address common questions and concerns caregivers have raised:

What changed	What it means in practice
Sniffing after administration is not required	Previously unclear whether patients needed to sniff to pull the medication deeper into the nasal cavity. The label now clarifies that normal administration is effective regardless of whether the patient sniffs. This matters for small children who may not follow instructions during an allergic emergency.
Accidental freezing does not render the device unusable	If neffy is accidentally frozen and thawed, it can still be used. Previously, accidental freezing was a concern that might lead caregivers to discard the device.
High temperature excursions up to 122°F permitted	Brief exposure to temperatures as high as 122°F (50°C) does not compromise product quality. This matters for devices stored in car glove compartments, diaper bags, or outdoor settings in warm climates.
Carrying case included with each prescription carton	Beginning this summer, each carton will include a carrying case. Availability is intended to improve day-to-day portability and reduce the barrier to carrying the device consistently.

How neffy Compares to Other Epinephrine Options

Epinephrine remains the only FDA-approved medication for anaphylaxis. It is not optional or a second-line measure: antihistamines like diphenhydramine (Benadryl) do not treat anaphylaxis and are not substitutes. For any patient at risk for anaphylaxis, carrying epinephrine is the medical standard.

The available options in the U.S. currently include:

Product	Format	Doses available	Weight-based dosing	Age restriction
EpiPen / EpiPen Jr	Intramuscular autoinjector (spring-loaded, needle-based)	0.3 mg (adult), 0.15 mg (Jr)	0.15 mg for 33 to 66 lbs; 0.3 mg for 66 lbs or more	No age floor, weight-based
Auvi-Q	Intramuscular autoinjector (needle-retractable, with voice instructions)	0.1 mg, 0.15 mg, 0.3 mg	Multiple doses for different weight ranges including 16 to 33 lbs	No age floor, weight-based
neffy 1 mg	Intranasal spray, no needle	1 mg	For patients 33 to 66 lbs (15 to 30 kg)	No age floor as of March 27, 2026
neffy 2 mg	Intranasal spray, no needle	2 mg	For patients 66 lbs or more (30 kg or more)	No age floor

The key practical difference is the delivery mechanism. EpiPen and Auvi-Q are effective, extensively studied intramuscular products with long track records. Auvi-Q’s voice instructions and needle-retraction design address some of the usability concerns associated with EpiPen, but both still require needle injection. neffy’s non-injectable format does not replace injection-based options but adds a choice for patients, families, and caregivers for whom needle administration is a real barrier.

Clinically, the two approaches should be considered equivalent in terms of epinephrine delivery based on the pharmacokinetic data. The choice between them is appropriately individualized based on patient preference, caregiver confidence, and clinical judgment.

The anaphylaxis delay problem: why needle hesitancy has clinical consequences Delayed epinephrine administration is the most common preventable factor in anaphylaxis fatalities. Studies consistently show that patients, parents, and bystanders delay using epinephrine for multiple reasons: uncertainty about whether symptoms are severe enough, concern about hurting the patient with a needle, fear of accidentally self-injecting, and lack of confidence in administering a needle device under pressure. Each minute of delay in epinephrine administration during a severe anaphylactic reaction increases the risk of cardiovascular and respiratory compromise. Antihistamines, commonly given as a first response, do not block the systemic cascade that makes anaphylaxis life-threatening. They treat urticaria (hives) and mild symptoms but cannot prevent or reverse anaphylactic shock. The clinical rationale for neffy is not that intranasal epinephrine is pharmacologically superior to injected epinephrine. The rationale is that a treatment which is equivalent in pharmacokinetics but significantly more likely to be used promptly by hesitant caregivers is clinically superior in practice, even if it is equivalent in theory.

Dosing, Administration, and What Caregivers Need to Know

Weight-based dosing is the rule:

neffy 1 mg: patients weighing 33 to 66 pounds (15 to 30 kg), any age
neffy 2 mg: patients weighing 66 pounds or more (30 kg or more), any age

Administration:

Remove the device from the case.
Hold the device upright with your thumb on the bottom and two fingers on the nozzle.
Insert the nozzle into one nostril. The patient does not need to sniff.
Press firmly to release the dose.
If symptoms do not improve within 5 minutes or worsen, administer a second dose in the same nostril from a second device.
Call 911 or go to the nearest emergency room immediately after use, even if symptoms improve.

Carry two devices: Current prescribing guidelines recommend carrying two epinephrine devices at all times because biphasic anaphylaxis, where symptoms return after initial improvement, can occur in approximately 1 in 5 anaphylaxis events.

Storage guidance: neffy can be stored at room temperature. Brief exposure up to 122°F is permitted. If accidentally frozen, it can be thawed and used. Keep the cap on between uses. The shelf life is 24 months at room temperature.

When to call 911: Always. Even after epinephrine administration and apparent symptom improvement, anaphylaxis requires emergency medical evaluation because of biphasic reaction risk.

What This Means for Schools, Daycares, and Emergency Preparedness

The removal of the age restriction has implications beyond individual families. Schools and daycare facilities with anaphylaxis emergency plans now have an additional option to consider for their youngest students who meet weight criteria. Many early childhood programs struggle with the needle administration training requirements that injectable epinephrine demands of staff, and untrained-user data showing effective neffy administration by non-medical personnel is directly relevant in these settings.

FARE (Food Allergy Research and Education) maintains resources for schools navigating food allergy emergency planning. ACAAI (American College of Allergy, Asthma and Immunology) provides clinical guidance on anaphylaxis preparedness. Both organizations’ resources may be updated to reflect the age restriction removal.

Sources

ARS Pharmaceuticals press release (March 27, 2026): ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label. GlobeNewswire.

ARS Pharmaceuticals IR page: ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement. ir.ars-pharma.com.

Original neffy 1 mg approval (May 2025): ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg. ir.ars-pharma.com.

FDA drug approval page: FDA approves epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. FDA.gov.

Pharmacy Times coverage: FDA Removes Age Restriction for neffy 1 mg, Expanding Access to Needle-Free Epinephrine. pharmacytimes.com. March 2026.

Contemporary Pediatrics coverage (with 89.2% real-world data): FDA removes age restriction for epinephrine nasal spray. contemporarypediatrics.com. March 2026.

Epinephrine delay and anaphylaxis fatalities: Epinephrine Use and Barriers to Carrying. PMC6290645.

Anaphylaxis overview: AAAAI Anaphylaxis.

Food allergy statistics: Facts and Statistics. FARE.

Patient and caregiver resources: FARE: Food Allergy Research and Education | ACAAI Anaphylaxis | AAAAI Anaphylaxis | neffy prescribing information

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Patients with known or suspected anaphylaxis risk should work with a board-certified allergist or immunologist to establish an individualized emergency action plan. Always call 911 after epinephrine administration, even if symptoms appear to resolve.

April 18, 2026

An Experimental Immunotherapy Just Got FDA Orphan Drug Status for Sarcoma. Here Is What the EFTISARC-NEO Trial Data Actually Shows.

📌 The essentials On April 15, 2026, the FDA granted Orphan Drug Designation to eftilagimod alfa (IMP321, Immutep) for the treatment of soft tissue sarcoma. The designation is based on data from the Phase 2 EFTISARC-NEO trial (NCT06128863), which met its primary endpoint with a median tumor hyalinization and fibrosis of 51.5% across 38 evaluable patients, well above both the trial’s prespecified threshold of 35% and the historical benchmark of approximately 15% with radiotherapy alone. What eftilagimod alfa is: a soluble form of LAG-3 protein that activates antigen-presenting cells to stimulate a broad immune response. It is not a checkpoint inhibitor. It works through a distinct, complementary mechanism to pembrolizumab. What Orphan Drug Designation means: eligibility for 7 years of market exclusivity, tax credits for clinical development costs, fee waivers, and enhanced FDA guidance. It does not mean the drug is approved or that approval is certain. Where the program stands: Immutep is reviewing its development strategy following the discontinuation of its Phase 3 TACTI-004 trial in head and neck cancer. The company has indicated the orphan designation may guide future decisions about advancing eftilagimod alfa in soft tissue sarcoma toward a late-stage neoadjuvant trial.

Soft tissue sarcoma is not a single disease. It is a family of more than 70 distinct histologic subtypes arising from connective tissues including fat, muscle, nerves, tendons, and blood vessels throughout the body. They are rare in aggregate, accounting for roughly 1% of adult malignancies in the United States, with approximately 13,000 new diagnoses and 5,000 deaths annually. That rarity has been part of the problem: the treatment landscape has moved slowly in comparison to more common cancers, and many subtypes have seen no meaningful new approvals in decades.

The current standard treatment for resectable soft tissue sarcoma is surgery, often with preoperative or postoperative radiation therapy. For higher-grade or larger tumors, neoadjuvant radiation before surgery is standard, but its response rate, measured by how much tumor the radiation kills before the surgeon removes it, has historically been modest. Pathologic response rates with radiotherapy alone typically produce median hyalinization and fibrosis around 15%. Chemotherapy is used in some settings but adds substantial toxicity with variable benefit.

Immunotherapy has largely failed to show meaningful activity in most sarcoma subtypes. The complex, immunosuppressive tumor microenvironment of soft tissue sarcomas has made checkpoint inhibitors less effective here than in more immunogenic tumors like melanoma or lung cancer. The EFTISARC-NEO trial is testing a different approach: rather than simply blocking inhibitory immune checkpoints, it adds a drug designed to actively stimulate the immune system’s antigen-presenting machinery at the same time.

On April 15, 2026, the FDA granted Orphan Drug Designation to eftilagimod alfa for soft tissue sarcoma, citing the EFTISARC-NEO data as the basis for the designation. This post covers what eftilagimod alfa is, what the trial actually showed, what the designation means in practice, and where this program sits relative to the broader and slowly evolving landscape of sarcoma treatment.

What Eftilagimod Alfa Is: A LAG-3 Agonist, Not a Checkpoint Inhibitor

Eftilagimod alfa (IMP321) is a soluble, recombinant form of LAG-3 (Lymphocyte Activation Gene-3), a protein expressed on the surface of activated T cells and natural killer cells. LAG-3 is commonly discussed in the context of immune checkpoint inhibitors, and several anti-LAG-3 antibodies (including relatlimab, which is approved in combination with nivolumab in melanoma) block LAG-3 on T cells to prevent exhaustion.

Eftilagimod alfa works completely differently. Rather than blocking LAG-3 on T cells, it acts as an agonist for MHC class II molecules on antigen-presenting cells (APCs), including dendritic cells and macrophages. By binding MHC class II on APCs, it activates them to present tumor antigens more efficiently to both CD4+ and CD8+ T cells, stimulating a broad adaptive and innate immune response. The goal is to transform a cold, immunosuppressed tumor microenvironment into a hot one where the immune system can recognize and attack the cancer.

This mechanism is complementary to pembrolizumab, which works by removing the inhibitory PD-1/PD-L1 brake on T cell activity. The hypothesis behind the EFTISARC-NEO combination is that eftilagimod alfa primes the immune system by activating APCs, pembrolizumab removes the brake on T cell activity, and radiotherapy releases tumor antigens by killing cancer cells, creating a coordinated, amplified anti-tumor immune response.

Why soft tissue sarcoma has been resistant to immunotherapy The tumor microenvironment of soft tissue sarcoma is characterized by low mutational burden in most subtypes, sparse T cell infiltration, and high levels of immunosuppressive cells including tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells. This immunosuppressive landscape is why single-agent checkpoint inhibitors have shown limited activity in most sarcoma subtypes: removing the brake on T cells is less effective when there are few T cells present and an environment actively working to suppress them. Radiotherapy can partially address this by releasing tumor antigens and creating an inflammatory signal that recruits immune cells. Eftilagimod alfa is designed to amplify that immunological priming step by activating APCs to process and present those antigens more effectively. The combination hypothesis is therefore mechanistically grounded: prime with efti, release antigens with radiation, and remove the T cell brake with pembrolizumab.

What Is Soft Tissue Sarcoma and Who Does It Affect?

Soft tissue sarcomas are cancers that arise from mesenchymal tissue, the connective tissues that form the structural framework of the body. The major histologic groups include:

Undifferentiated pleomorphic sarcoma (UPS): Among the most common high-grade subtypes in adults. Aggressive with a high rate of local and distant recurrence.
Liposarcoma: Arises from fat tissue. Several subtypes with varying aggressiveness, from well-differentiated (low-grade) to dedifferentiated (high-grade).
Leiomyosarcoma: Arises from smooth muscle. Common in the uterus and retroperitoneum.
Synovial sarcoma: Affects primarily young adults and adolescents. One of the few subtypes with a recently approved immunotherapy (afami-cel, discussed below).
Myxofibrosarcoma: Common in the extremities of older adults. High local recurrence rate.

EFTISARC-NEO specifically enrolled patients with grade 2 or 3, stage III sarcomas of the extremities or trunk with specific eligible histologies. The study was conducted at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, primarily funded through an approved grant from the Polish Medical Research Agency.

Most soft tissue sarcomas present as painless masses. Diagnosis typically requires core needle biopsy and centralized pathologic review at a center with sarcoma expertise, because accurate subtype identification is critical for treatment planning. Management of high-grade resectable sarcoma typically involves a multidisciplinary team including surgical oncology, radiation oncology, and medical oncology.

The EFTISARC-NEO Trial: What the Data Shows

Trial design

EFTISARC-NEO (NCT06128863) is a Phase 2, single-arm, single-center investigator-initiated study conducted at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. It evaluates eftilagimod alfa administered concurrently with pembrolizumab (Keytruda, Merck) and standard radiotherapy as neoadjuvant treatment in patients with resectable soft tissue sarcoma.

Eligible patients were adults aged 18 or older with ECOG performance status 0 or 1, grade 2 or 3 sarcomas, and eligible histologies including undifferentiated pleomorphic sarcoma, myxofibrosarcoma, pleomorphic liposarcoma, and pleomorphic leiomyosarcoma, among others. Tumors were required to be located in the deep extremities, girdles, or superficial trunk. No adjuvant treatment was permitted after surgery, with 24 months of regular follow-up.

The treatment sequence: eftilagimod alfa and pembrolizumab administered during the 25-fraction radiotherapy course, followed by surgical resection. The primary endpoint was tumor hyalinization and fibrosis at the time of surgical resection.

The primary endpoint: what tumor hyalinization and fibrosis actually measures

Tumor hyalinization and fibrosis is a validated histopathologic endpoint in soft tissue sarcoma that quantifies the proportion of the tumor that has been replaced by scar tissue and devitalized cells after treatment, reflecting treatment-induced tumor cell kill. It is measured by a pathologist examining the surgical specimen after tumor removal. Higher hyalinization and fibrosis percentages indicate more extensive tumor destruction.

This endpoint is clinically meaningful because it has been associated with improved outcomes in multiple sarcoma studies. A higher pathologic response rate at surgery predicts better overall survival and recurrence-free survival compared to lower response rates, even though it is measured at a single timepoint. It is analogous in concept to pathologic complete response (pCR) used as a surrogate endpoint in breast cancer neoadjuvant trials.

The historical benchmark with radiotherapy alone in comparable patient populations is approximately 15% median hyalinization and fibrosis. The EFTISARC-NEO trial was designed with an ambitious prespecified threshold: the trial would be considered successful if the median exceeded 35%.

Results

Outcome	Result	Context
Evaluable patients (full analysis)	38	Target enrollment completed January 2025
Median tumor hyalinization/fibrosis	51.5%	vs 35% prespecified target; vs ~15% historical with RT alone
Patients achieving 35% or greater	Majority of evaluable patients	Exceeded prespecified threshold
Consistency across subtypes	Yes	Benefit seen across multiple STS histologies
Grade 3 or higher toxicity from efti or pembrolizumab	0	No high-grade immune-related toxicity
Surgical delays related to treatment	0	All patients proceeded to planned surgery
Translational immune data	Showed immune activation consistent with mechanism of action	APC activation, CD4+ and CD8+ T cell engagement

Source: ESMO Congress 2025 Proffered Paper presentation. CTOS 2025 Annual Meeting Oral Presentation. Immutep press release April 15, 2026.

The 51.5% median is more than a 3-fold increase over the 15% historical benchmark. The fact that no patients had their surgery delayed due to treatment toxicity is a practical clinical finding that matters in the neoadjuvant setting, where surgery timing is part of the overall treatment plan. The translational data showing immune activation consistent with the proposed mechanism of action, including evidence of APC engagement and downstream T cell responses in the tumor microenvironment, supports the mechanistic hypothesis rather than simply showing an empirical effect.

Full detailed results from the complete 38-patient analysis were presented at ESMO Congress 2025 as a Proffered Paper, a higher-tier presentation format at ESMO, and at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting.

What Orphan Drug Designation Means and What It Does Not

FDA Orphan Drug Designation is granted to drugs intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the United States. Soft tissue sarcoma meets this threshold.

The designation provides:

7 years of market exclusivity after approval, protecting against generic or biosimilar competition
Tax credits covering 25% of qualified clinical trial costs
Fee waivers for FDA application fees
Enhanced regulatory guidance and potential for more frequent FDA interaction during development
Eligibility for Orphan Drug grants for qualifying organizations

The European Medicines Agency had already granted a similar designation for eftilagimod alfa in soft tissue sarcoma before the FDA designation, establishing parallel orphan status on both sides of the Atlantic.

What the designation does not mean: it is not approval, not a guarantee of approval, and does not reduce the evidence standard required for approval. A drug with Orphan Drug Designation still needs to demonstrate substantial evidence of safety and efficacy in adequate and well-controlled clinical studies to be approved. The designation is a development incentive, not a regulatory shortcut.

The TACTI-004 Context: Why This Is a Pivotal Moment for Eftilagimod Alfa

Understanding the significance of the soft tissue sarcoma program requires understanding what happened in Immutep’s flagship program.

The TACTI-004 trial was a Phase 3 study evaluating eftilagimod alfa in combination with pembrolizumab for first-line treatment of head and neck squamous cell carcinoma (HNSCC), the largest and most advanced clinical program in eftilagimod alfa’s development history. In early 2026, Immutep announced the discontinuation of TACTI-004, citing the emerging competitive landscape in first-line HNSCC where multiple approved combination regimens had raised the bar for demonstrating meaningful superiority.

The discontinuation was a significant setback for the broader eftilagimod alfa program. However, the company has been careful to distinguish the HNSCC competitive context from the sarcoma setting, where there is no equivalent competitive landscape and the therapeutic need remains largely unmet.

For soft tissue sarcoma specifically, the evidence picture is different. The EFTISARC-NEO results are in a disease with no approved immunotherapy in the neoadjuvant setting, limited treatment advances in recent years, and a validated pathologic endpoint with prognostic relevance. The Orphan Drug Designation provides development incentives that could support moving toward a formal registrational trial.

The Broader Sarcoma Treatment Landscape: Where This Fits

The soft tissue sarcoma treatment landscape has seen modest but meaningful recent progress after years of relative stagnation.

The most directly relevant recent approval is afami-cel (Tecelra, Adaptimmune), the first T cell receptor-engineered cell therapy approved by the FDA, which received approval in August 2024 for unresectable or metastatic synovial sarcoma in adults and adolescents 16 or older after prior treatment. Afami-cel targets MAGE-A4, an antigen expressed on synovial sarcoma cells, and produced an overall response rate of 39% in the pivotal trial. It represents the first approved immunotherapy in soft tissue sarcoma, opening the door to immune-based approaches in a tumor type where they had previously largely failed.

Eftilagimod alfa is pursuing a different subtype of sarcoma, a different treatment setting (neoadjuvant rather than metastatic), and a different mechanism (APC activation rather than T cell receptor engineering). The two programs are not in competition; they address different clinical scenarios within the same broad disease category.

Other relevant pipeline programs in soft tissue sarcoma include olaratumab, which is being re-evaluated after its initial Phase 3 failure, and multiple combinations exploring CDK4/6 inhibitors for well-differentiated and dedifferentiated liposarcoma, which overexpresses CDK4.

What This Means for Patients and Oncologists

For patients currently being treated for resectable soft tissue sarcoma, eftilagimod alfa is investigational. It is not approved and is not available outside of clinical trials. The EFTISARC-NEO trial completed enrollment in January 2025 and is currently in the follow-up period. Immutep has indicated that the Orphan Drug Designation may support planning a late-stage neoadjuvant trial, but no registration trial has been announced or started.

For patients interested in sarcoma clinical trial options, ClinicalTrials.gov is the primary resource for identifying open enrollment studies. The Sarcoma Foundation of America and the Sarcoma Alliance maintain patient-facing resources on sarcoma subtypes, treatment options, and clinical trial access. Sarcoma care is highly specialized, and management at a National Cancer Institute-designated cancer center or a dedicated sarcoma program is strongly recommended for diagnosis and treatment planning.

For clinicians, the EFTISARC-NEO results represent the strongest prospective data for an immunotherapy-containing regimen in resectable high-grade soft tissue sarcoma to date, though the single-arm, single-center Phase 2 design limits direct actionability without confirmatory data. The translational correlates presented at ESMO 2025 and CTOS 2025 supporting the proposed mechanism of action are a meaningful addition to the evidence base.

For context on how the FDA has been using orphan drug and rare disease designations alongside other regulatory tools to accelerate rare disease drug development in 2026, see our post on the UX111 gene therapy for Sanfilippo syndrome, which holds multiple FDA rare disease designations and is currently under review, and our post on the first gene therapy for genetic deafness, which was approved under the Rare Pediatric Disease PRV program.

Sources

Immutep Orphan Drug Designation press release: Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma. GlobeNewswire. April 15, 2026.

Immutep company website: Eftilagimod Alfa Pipeline. immutep.com.

EFTISARC-NEO trial registration: NCT06128863. ClinicalTrials.gov.

Targeted Oncology ODD coverage: FDA Grants Orphan Drug Designation to Eftilagimod Alfa for Soft Tissue Sarcoma. targetedonc.com. April 2026.

OncLive primary endpoint coverage: Eftilagimod Alfa/Radiotherapy/Pembrolizumab Yields Favorable Hyalinization/Fibrosis in Soft Tissue Sarcoma. onclive.com. May 2025.

CancerNetwork coverage: Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma. cancernetwork.com. May 2025.

Targeted Oncology Phase 2 results: EFTISARC-NEO Trial Meets Primary End Point in Soft Tissue Sarcoma. targetedonc.com. May 2025.

Afami-cel FDA approval: FDA approves afami-cel for synovial sarcoma. FDA.gov. August 2024.

FDA Orphan Drug Designation program: Orphan Drug Designations and Approvals. FDA.gov.

Orphan Drug market exclusivity and incentives: Designating an Orphan Product. FDA.gov.

LAG-3 biology reference: LAG-3 and its role in cancer immunotherapy. PMC7938019.

STS tumor microenvironment: Tumor Microenvironment in Soft Tissue Sarcoma. PMC9912345.

Hyalinization/fibrosis as prognostic endpoint: Pathologic Response in Soft Tissue Sarcoma. PMC4580342.

Soft tissue sarcoma overview: Soft Tissue Sarcoma. American Cancer Society.

Patient resources: Sarcoma Foundation of America | Sarcoma Alliance | ClinicalTrials.gov: Soft Tissue Sarcoma | NCI Sarcoma Information

Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. Eftilagimod alfa is investigational and not currently FDA-approved for soft tissue sarcoma or any other indication in the United States. Treatment decisions for soft tissue sarcoma should be made in consultation with a qualified oncologist at a center with sarcoma expertise.

April 17, 2026

The FDA Approved Foundayo. It Also Required These Post-Marketing Studies. Here Is What That Means and Why It Is Normal Practice.

📌 The essentials Foundayo (orforglipron) was approved by the FDA on April 1, 2026 as the first non-peptide, small molecule oral GLP-1 receptor agonist for chronic weight management. It was approved 50 days after NDA submission under the Commissioner’s National Priority Voucher (CNPV) program, the fastest approval of a new molecular entity since 2002. As part of the FDA approval letter, Eli Lilly is required to conduct several post-marketing studies. Per the FDA approval letter, these include: evaluation of major adverse cardiovascular events (MACEs) and drug-induced liver injury (DILI); assessment of delayed gastric emptying and aspiration risk; a lactation study to measure drug concentrations in breast milk; pediatric trials in patients aged 6 to 12; and pregnancy registry data. The FDA is also requiring enhanced pharmacovigilance for drug-induced liver injury for 5 years following approval, including expedited reporting of serious cases. Lilly has also separately released ACHIEVE-4 trial data showing non-inferior MACE risk compared to insulin glargine, which directly addresses the cardiovascular monitoring requirement. What this does not mean: post-marketing study requirements are routine for obesity medications and do not reflect a finding that the drug is unsafe. Foundayo was approved based on the ATTAIN clinical program data. The post-marketing studies reflect normal FDA practice of continuing safety surveillance after approval, particularly for a new molecular class with limited long-term data.

Foundayo (orforglipron) was the most talked-about obesity drug approval of 2026. Not just because of what it is, the first oral GLP-1 receptor agonist that does not require a peptide injection and has no food or water restrictions, but because of how fast it happened. The FDA approved it 50 days after Eli Lilly submitted the NDA, making it the fastest approval of a new molecular entity since 2002, and the first new molecular entity approved under the Commissioner’s National Priority Voucher program.

What received less coverage in that story is a standard part of every major drug approval: the FDA’s post-marketing study requirements. These are the conditions attached to the approval letter specifying additional clinical studies Lilly must conduct now that the drug is on the market. A Reuters report noted some of these requirements shortly after the approval. This post looks directly at the FDA approval letter, explains what each requirement is and why it exists, and puts the requirements in context for the broader GLP-1 obesity treatment landscape.

For a full overview of what Foundayo is, how orforglipron works, and what the ATTAIN clinical trial data showed, see our main post: Foundayo: The First Once-Daily GLP-1 Pill for Weight Loss.

What Orforglipron Is and Why It Is Different

Orforglipron is a small molecule, non-peptide GLP-1 receptor agonist. Every GLP-1 receptor agonist currently approved in the United States before Foundayo, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity), is based on a peptide molecule, a chain of amino acids structurally similar to the natural GLP-1 hormone. Because peptides are broken down in the stomach, most of these drugs are injectable. The one exception, Rybelsus (oral semaglutide), requires fasting for 30 minutes and a small amount of water to achieve adequate absorption.

Orforglipron is fundamentally different. It is a small organic molecule, not a peptide, that binds to and activates the same GLP-1 receptor. Its small molecule structure allows it to survive oral digestion without the absorption restrictions that peptide-based oral semaglutide requires. It can be taken at any time of day, with or without food, and without water restrictions.

This is a genuine pharmacological advance. The practicality difference between taking a once-weekly injection, taking a pill at a specific time under fasting conditions, and taking a pill whenever you want matters for real-world adherence, particularly among the more than 90% of eligible patients who are not currently on any GLP-1 therapy.

The ATTAIN clinical program demonstrated that in the ATTAIN-1 trial, patients taking the highest dose of Foundayo who stayed on treatment lost an average of 27.3 pounds (12.4% of body weight) compared to 2.2 pounds (0.9%) with placebo. Across all trial completers regardless of dose escalation, average weight loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo. The drug also showed reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.

What Post-Marketing Studies Are and Why They Are Routine

Before getting into the specific requirements for Foundayo, it is worth explaining what post-marketing study requirements actually are, because the framing of “FDA requires studies” can sound more alarming than it is.

Every major drug approval, particularly for new molecular entities in new drug classes, comes with post-marketing commitments and requirements. These fall into two categories:

Post-marketing commitments (PMCs): voluntary agreements where the sponsor agrees to conduct additional studies, often to explore dosing, new populations, or drug interactions.

Post-marketing requirements (PMRs): studies the FDA requires by law because specific safety questions cannot be adequately answered through nonclinical data or observational surveillance alone. They are written into the approval letter.

The distinction matters: PMRs do not mean the drug has a safety problem. They mean the FDA identified specific questions about safety in populations or settings that were not fully characterized in the pivotal trial program, and that randomized, controlled prospective data is needed to answer those questions properly. This is how responsible post-market surveillance of new drug classes works.

GLP-1 receptor agonists as a class have been subject to ongoing FDA safety monitoring since the class was first approved, including reviews of suicidal ideation reports (for which the FDA ultimately concluded in 2024 that the available evidence does not support a causal relationship between GLP-1 receptor agonists and suicidal behavior), thyroid cancer signals, and pancreatitis risk. Foundayo’s post-marketing requirements build on this established framework.

The Specific Post-Marketing Requirements for Foundayo

Based on the FDA approval letter and coverage of the approval letter contents, the following post-marketing study requirements are in place for Foundayo:

1. Cardiovascular outcomes (MACEs)

What is required: A prospective randomized trial evaluating major adverse cardiovascular events (MACEs), specifically heart attack, stroke, cardiovascular death, and unstable angina requiring hospitalization.

Why this is required: The FDA requires all new diabetes and obesity drugs to demonstrate cardiovascular safety through adequate CVOT (cardiovascular outcomes trial) data. The pivotal ATTAIN trials were designed to demonstrate weight loss efficacy and were not powered or designed as cardiovascular outcomes studies. The FDA therefore requires a dedicated CVOT to characterize the full cardiovascular risk-benefit profile of orforglipron in a larger population over longer follow-up.

Current status: Lilly has already released results from the Phase 3 ACHIEVE-4 trial (NCT05803421), which evaluated orforglipron versus insulin glargine in patients with type 2 diabetes. ACHIEVE-4 showed non-inferior risk for MACEs compared to insulin glargine and detected no safety signal for drug-induced liver injury. Lilly has indicated it plans to submit an NDA for Foundayo in type 2 diabetes by the end of Q2 2026, supported by this data. The ACHIEVE-4 results partially address the cardiovascular monitoring requirement, though the FDA will specify the scope of ongoing data requirements.

2. Drug-induced liver injury (DILI)

What is required: Enhanced pharmacovigilance for drug-induced liver injury for 5 years following approval, including expedited reporting of serious cases and periodic cumulative safety analyses.

Why this is required: New small molecule drugs, particularly those in new molecular classes, are monitored carefully for hepatotoxicity signals that may not have been apparent in pivotal trials. The ACHIEVE-4 trial found no safety signal for liver injury, but the FDA is requiring systematic prospective surveillance across the broader post-market population.

Context: Drug-induced liver injury is one of the most common reasons for post-market drug withdrawals and is a priority safety monitoring target for the FDA across drug classes. The 5-year enhanced surveillance period is a standard precautionary measure for new molecular entities.

3. Delayed gastric emptying and aspiration risk

What is required: Assessment of the drug’s effects on gastric emptying rate and associated aspiration risk, particularly relevant in the context of anesthesia and sedation procedures.

Why this is required: GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action, and this effect has clinical implications for patients undergoing procedures requiring anesthesia or sedation. The American Society of Anesthesiologists has issued guidance on GLP-1 agonists in the perioperative setting, recommending holding these medications before procedures. The FDA’s requirement for orforglipron specifically is to characterize the gastric emptying effect of the oral formulation, which may have different pharmacokinetics than injectable versions.

4. Lactation study

What is required: A study measuring drug concentrations in breast milk in nursing mothers.

Why this is required: The pivotal trials excluded pregnant and breastfeeding women. The FDA requires a lactation study to determine the extent to which orforglipron is transferred into breast milk, as this directly informs prescribing decisions for women who are breastfeeding and clinicians counseling them on the drug’s safety in this setting.

5. Pediatric trials (ages 6 to 12)

What is required: Clinical trials in pediatric patients aged 6 to 12 years with obesity.

Why this is required: The Pediatric Research Equity Act (PREA) generally requires sponsors to study new drugs in pediatric populations unless a waiver is granted. The FDA waived the under-6 age group, citing limited expected use and therapeutic benefit in very young children. The 6 to 12 age group is included given that childhood and adolescent obesity is a significant clinical problem and clinicians will eventually prescribe this drug in younger patients.

6. Pregnancy registry

What is required: A structured pregnancy exposure registry to capture outcomes in women who become pregnant while taking Foundayo.

Why this is required: GLP-1 medications should be discontinued before attempting conception because of potential fetal effects, but unintended pregnancies during treatment are well documented across this drug class. The pregnancy registry will systematically capture data on fetal outcomes in women with inadvertent first-trimester exposure, building a real-world safety database that cannot be generated from controlled trials.

Hair loss: a side effect, not a post-marketing study requirement The stub post on this topic framed hair loss as equivalent to the post-marketing study requirements above. This needs clarification. Hair loss is listed as a common side effect in the Foundayo prescribing information, alongside nausea, constipation, diarrhea, and other GI effects. It was observed in the ATTAIN trials and is included in the approved label. It is not a specific named post-marketing study requirement in the same category as the CVOT or DILI monitoring. Hair loss has been observed with GLP-1 medications more broadly and is believed to be related to the physiological stress of rapid weight loss (telogen effluvium) rather than a direct drug effect. Patients who experience hair loss on Foundayo should discuss it with their prescriber; it is typically reversible as weight stabilizes.

Why This Pattern Is Consistent With the CNPV Approval Context

The speed of Foundayo’s approval under the CNPV program, 50 days from NDA submission, is directly relevant to understanding why the post-marketing study package is robust. The CNPV program compresses FDA review timelines dramatically but does not reduce the evidentiary standard for approval. For a novel molecular entity in a new drug class, some safety questions that would normally be answered in a longer review process are instead addressed through post-market commitments.

This is not unique to Foundayo. Wegovy HD (semaglutide 7.2 mg), which was also approved under the CNPV program, similarly came with post-marketing monitoring requirements. The CNPV program approval speed and the post-marketing study requirements are two parts of the same regulatory approach: approve based on strong efficacy and acceptable safety from the clinical program, then require prospective data to fill the remaining gaps systematically.

The FDA’s approach to Foundayo reflects a broader evolution in how it handles obesity drug safety. After the experience with earlier obesity drugs including sibutramine (withdrawn for cardiovascular risk) and fenfluramine (withdrawn for valvular heart disease), the FDA has taken a systematically cautious approach to post-market safety surveillance for this class, requiring dedicated CVOT data and structured monitoring programs.

What Patients Taking Foundayo Should Know

If you are taking or considering Foundayo for weight management, the post-marketing study requirements do not indicate that the drug is unsafe. They indicate that the FDA is conducting the normal, responsible surveillance that accompanies every major new drug class approval.

The safety profile documented in the ATTAIN trials showed that the most common side effects were gastrointestinal, including nausea, constipation, diarrhea, vomiting, and abdominal pain. These are consistent with the established profile of the GLP-1 receptor agonist class. Hair loss was also reported and is typically temporary.

Key practical points:

Foundayo should be discontinued at least 2 months before planned conception, consistent with guidance across the GLP-1 class. Effective contraception during treatment is recommended.
Inform your anesthesia provider that you are taking Foundayo before any scheduled procedure requiring general anesthesia or deep sedation, as the gastric emptying effect is clinically relevant in this setting.
Report any symptoms of liver injury, including unusual fatigue, jaundice, or upper right abdominal pain, to your prescriber promptly.
Do not use Foundayo with other GLP-1 receptor agonists.

For more on how GLP-1 medications interact with reproductive health considerations, see our post on GLP-1 medications, PCOS, and the fertility and pregnancy evidence in 2026.

Sources

FDA approval announcement: FDA Approves First New Molecular Entity Under National Priority Voucher Program. FDA.gov. April 1, 2026.

FDA approval letter: Foundayo (orforglipron) NDA approval letter. accessdata.fda.gov. April 1, 2026.

Lilly approval press release: FDA Approves Lilly’s Foundayo (orforglipron). investor.lilly.com. April 1, 2026.

Clinical Trials Arena post-marketing coverage: Lilly debuts more Foundayo data as FDA requests post-marketing trials. clinicaltrialsarena.com. April 16, 2026.

Pharmacally post-marketing requirements detail: FDA Requires Extensive Postmarketing Safety Data for Foundayo. pharmacally.com. April 2026.

Foundayo drug history: Foundayo (orforglipron) FDA Approval History. drugs.com.

ACHIEVE-4 trial registration: NCT05803421. ClinicalTrials.gov.

FDA GLP-1 and suicidal ideation review: Information About Suicidal Thoughts, Behavior, and GLP-1 Receptor Agonists. FDA.gov.

Post-marketing studies FDA guidance: Postmarketing Studies and Clinical Trials: Guidance for Industry. FDA.gov.

GLP-1 gastric emptying clinical review: Delayed Gastric Emptying and GLP-1 Receptor Agonists. PMC10183139.

PREA pediatric requirement: Pediatric Research Equity Act. FDA.gov.

DILI overview: Drug-Induced Liver Injury. StatPearls. NCBI.

ASA GLP-1 perioperative guidance: American Society of Anesthesiologists Guidance on GLP-1 Receptor Agonists. asahq.org.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about obesity treatment, including whether Foundayo is appropriate for your situation, should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, current medications, and weight management goals.

April 16, 2026

The FDA Just Removed Boxed Warnings From Six Hormone Therapy Products. Here Is What Changed, What Stayed, and Why It Matters.

The essentials: On February 12, 2026, the FDA approved drug labeling changes to six menopausal hormone therapy products, removing risk statements related to cardiovascular disease, breast cancer, and probable dementia from their boxed warnings. This is the first batch of approvals. At the FDA’s request, 29 drug companies have submitted proposed labeling changes, with additional approvals expected as submissions are reviewed. The six products affected: Bijuva (estradiol and progesterone), Divigel (estradiol gel), Cenestin (synthetic conjugated estrogens A), Enjuvia (synthetic conjugated estrogens B), Prometrium (progesterone), and Estring (estradiol vaginal system). What was NOT removed: the boxed warning for endometrial cancer remains on systemic estrogen-alone products. This is a clinically important retained warning that all prescribers and patients should be aware of. Context: the FDA initiated this label review in November 2025 following a comprehensive scientific literature review, an expert advisory panel in July 2025, and a public comment period. The 29-company label update process is ongoing.

Menopausal hormone therapy has had a complicated two decades in American medicine. In the early 2000s, the Women’s Health Initiative (WHI), a landmark landmark trial, reported findings that were widely interpreted as showing hormone therapy increased risks of breast cancer, heart disease, stroke, and blood clots. The FDA added boxed warnings to hormone therapy products reflecting those risks. Prescribing dropped dramatically, and it never fully recovered.

The scientific community has spent years re-examining those findings. The primary methodological critique has been consistent: the average age of WHI participants was 63, more than a decade past the average age of menopause onset. The formulation used (conjugated equine estrogen plus medroxyprogesterone acetate, a synthetic progestin) is not representative of current prescribing, which increasingly favors body-identical hormones. And subsequent analyses specifically in younger women who started HRT closer to menopause onset showed a substantially different risk profile.

On February 12, 2026, the FDA acted on that updated evidence. It approved the removal of cardiovascular disease, breast cancer, and probable dementia risk statements from the boxed warnings of six hormone therapy products. The action is the first step of a broader process affecting 29 drug products.

What a Boxed Warning Is and Why Its Removal Matters

A boxed warning is the FDA’s most prominent safety communication on a drug label. It appears inside a bold black border at the top of the prescribing information and is reserved for serious or life-threatening risks. Its presence signals to prescribers that the drug carries risks serious enough to warrant special consideration and monitoring.

For many prescribers and patients, a boxed warning is functionally a deterrent. The presence of a cancer warning or heart disease warning on hormone therapy labels has contributed to underutilization for more than two decades. The utilization gap is stark: in 2020, approximately 41 million U.S. women were between ages 45 and 64, yet only about 2 million women ages 46 to 65 received a hormone therapy prescription. That is roughly 1 in 20.

Removing those specific risk statements from the boxed warning reflects the FDA’s conclusion, after comprehensive scientific review, that the evidence no longer supports placing cardiovascular disease, breast cancer, and probable dementia in the most prominent warning position on the label.

What Was Removed and What Was Retained

This distinction is clinically critical and was largely absent from most coverage of this announcement.

Removed from boxed warnings (for the six approved products):

Risk statements related to cardiovascular disease
Risk statements related to breast cancer
Risk statements related to probable dementia

Retained and not changed:

The boxed warning for endometrial cancer remains on systemic estrogen-alone products. This warning is not being removed because it reflects a well-established, causal biological relationship: unopposed estrogen in women with an intact uterus increases the risk of endometrial hyperplasia and endometrial cancer. This is why women with an intact uterus who use systemic estrogen-alone therapy require concurrent progestogen. This warning is not a legacy artifact of the WHI. It reflects established reproductive endocrinology and has not been reconsidered in this process.
Contraindications remain in the prescribing information for all updated products, including active arterial thromboembolic disease (stroke, myocardial infarction), known or suspected breast cancer, known or suspected estrogen-dependent neoplasia, undiagnosed abnormal uterine bleeding, active liver dysfunction, and known hypersensitivity.

Why the endometrial cancer warning staying matters Estrogen stimulates growth of the uterine lining. Without progesterone or progestogen to counteract that stimulation, prolonged unopposed estrogen exposure in women with a uterus can cause endometrial hyperplasia and increase the risk of endometrial cancer. This is not a disputed risk. It is a well-characterized biological mechanism that has been known since the 1970s. The current label update specifically preserves this warning for systemic estrogen-alone products (such as estradiol patches, oral estrogens, and estradiol gels like Divigel). Women with an intact uterus who use systemic estrogen therapy must be prescribed a progestogen alongside it. This requirement does not change with the February 2026 label updates.

The Scientific Evidence Behind the Label Changes

The FDA’s decision followed a systematic process that included an expert advisory panel in July 2025, a comprehensive literature review, and a public comment period. The relevant evidence base is substantial and has been building for years.

The WHI reanalysis and the timing hypothesis

The Women’s Health Initiative enrolled women with an average age of 63. When researchers reanalyzed the WHI data stratifying by age at enrollment and time since menopause, a different picture emerged. Women who started HRT within 10 years of menopause onset or before age 60 showed different outcomes than those who started more than 10 years post-menopause. This is sometimes called the “timing hypothesis” or “window of opportunity.”

The Kronos Early Estrogen Prevention Study (KEEPS) enrolled women aged 42 to 58 within 36 months of their final menstrual period and found that low-dose oral or transdermal estradiol started early in the menopausal transition did not increase cardiovascular risk over four years.

The Early versus Late Intervention Trial with Estradiol (ELITE) randomized women to estradiol or placebo based on time since menopause (fewer than 6 years, or more than 10 years). It found that estradiol slowed progression of subclinical atherosclerosis in women who started within 6 years of menopause but not in those who started later, directly supporting the timing hypothesis.

The Menopause Society’s 2022 position statement concluded that the benefits of hormone therapy outweigh the risks for most healthy symptomatic women who begin treatment under age 60 or within 10 years of menopause, and that the WHI data should not be applied indiscriminately to all hormone therapy users.

The FDA’s February 2026 label update represents the regulatory translation of this accumulated body of evidence.

What the updated labels say about timing

The FDA’s updated labeling recommendation is to start systemic HRT within 10 years of menopause onset or before age 60. This is not an absolute contraindication for later initiation, but it is a clinical guidance point that the label will now include explicitly.

The benefit claims: what the evidence actually supports

The HHS fact sheet accompanying this announcement cited risk reductions including cardiovascular diseases by up to 50%, Alzheimer’s disease by 35%, and bone fractures by 50 to 60%. These figures come from observational analyses and secondary endpoint analyses from the relevant literature. They represent the upper estimates of potential benefit from studies of women who initiated HRT at younger ages and are not uniformly established as causal effect sizes across all formulations and populations. The fracture reduction data is the most consistently supported. The cardiovascular benefit in the timing window is biologically plausible and supported by the evidence above. The Alzheimer’s protection data is promising but still the subject of ongoing research. The appropriate interpretation of these figures is that they reflect the potential magnitude of benefit in women who use HRT appropriately, not guaranteed outcomes for every individual patient.

Which Products Are Affected and Their Updated Labels

The six products in the first batch of approved labeling changes represent all four major categories of menopausal HRT:

Product	Category	Active ingredient	Updated label
Bijuva	Systemic combination (estrogen plus progestogen)	Estradiol and progesterone	Link
Divigel	Systemic estrogen-alone (topical gel)	Estradiol	Link
Cenestin	Systemic estrogen-alone (oral)	Synthetic conjugated estrogens A	Link
Enjuvia	Systemic estrogen-alone (oral)	Synthetic conjugated estrogens B	Link
Prometrium	Systemic progestogen-alone	Progesterone (micronized)	Link
Estring	Topical vaginal estrogen (ring)	Estradiol vaginal system	Link

The remaining 23 drug companies that submitted proposed labeling changes are still in the review process. Their products will be updated as submissions are approved. The FDA’s menopausal hormone therapies updated prescribing information page will track additional products as they are approved.

What This Means for Women and Clinicians

For women currently using or considering HRT

The removal of boxed warnings for cardiovascular disease, breast cancer, and probable dementia does not mean these risks are zero. It means the FDA has concluded that the evidence does not support placing them in the most prominent risk-warning position for the indicated population (women using HRT appropriately, typically within 10 years of menopause onset and before age 60).

HRT remains an individualized decision that should account for personal risk factors including:

Personal or family history of breast cancer
History of blood clots, stroke, or cardiovascular disease
Liver disease
Undiagnosed vaginal bleeding
Time since menopause and age at initiation

The Menopause Society’s practitioner finder can help identify clinicians with menopause medicine certification who are equipped to discuss the updated evidence and individual risk profiles.

For clinicians

The label changes affect prescribing information and patient counseling conversations. Women who have avoided HRT because of the boxed warnings may now re-engage with the question, and clinicians should be prepared to have evidence-based conversations about individualized benefit-risk assessment. The retained endometrial cancer warning for estrogen-alone products, the continued contraindications, and the timing guidance are all still present in the label and remain clinically operative.

What has not changed

HRT still requires a prescription. Contraindications still apply. The timing guidance (within 10 years of menopause onset or before age 60 for systemic HRT) is a recommendation, not an absolute cutoff. Women with an intact uterus still need progestogen with systemic estrogen. The conversations between clinician and patient remain the appropriate framework for HRT decisions.

For related coverage on how this label change fits into the broader reassessment of hormone therapy in women’s health, see our posts on vaginal estrogen therapy safety in endometrial cancer survivors, hormone therapy underuse in women with premature ovarian insufficiency, and new 2026 cervical cancer screening guidelines allowing self-collection.

Sources

FDA press announcement: FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. FDA.gov. February 12, 2026.

HHS announcement (November 2025): HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA.gov. November 10, 2025.

HHS fact sheet: FACT SHEET: FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products. HHS.gov. November 10, 2025.

FDA updated prescribing information tracker: Menopausal Hormone Therapies with Updated Prescribing Information. FDA.gov.

Updated label: Bijuva: accessdata.fda.gov.

Updated label: Divigel: accessdata.fda.gov.

Updated label: Cenestin: accessdata.fda.gov.

Updated label: Enjuvia: accessdata.fda.gov.

Updated label: Prometrium: accessdata.fda.gov.

Updated label: Estring: accessdata.fda.gov.

Contemporary OB/GYN coverage: FDA updates labels on multiple menopausal hormone therapies. contemporaryobgyn.net. February 12, 2026.

Pharmacy Times coverage: FDA Approves Drug Labeling Changes to 6 Menopausal Hormone Therapy Products. pharmacytimes.com. 2026.

Prism News coverage: FDA narrows boxed warnings for six menopausal hormone therapies. prismnews.com. February 13, 2026.

KEEPS trial: Harman SM et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005. PMC3678904.

ELITE trial: Hodis HN et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016.

Menopause Society 2022 position statement: The 2022 Menopause Society Position Statement on Hormone Therapy. menopause.org.

WHI background: Women’s Health Initiative. National Heart, Lung, and Blood Institute.

Menopause Society practitioner finder: Find a Menopause Healthcare Practitioner.

Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about hormone therapy should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, risk factors, and symptom burden.

April 14, 2026

Cancer Outcomes Are Worse for LGBTQ+ Patients. The Research Infrastructure to Address That Is Just Getting Started.

📌 What this post covers In 2024, the American Cancer Society published its first dedicated report on cancer in LGBTQ+ people, and the findings were stark: LGBTQ+ individuals are more likely to develop certain cancers, face more barriers to screening and diagnosis, and report worse experiences of care than their heterosexual and cisgender counterparts. A central driver of these disparities is a problem that sounds administrative but has real clinical consequences: most health systems still do not routinely collect sexual orientation and gender identity (SOGI) data. Without that data, oncology teams cannot identify these patients, tailor their care, or study outcomes in any systematic way. This post covers what the evidence shows about LGBTQ+ cancer disparities, why the data collection gap is central to the problem, and what the research community is doing to address it, including a new national research center funded by the American Cancer Society specifically to improve outcomes in this population.

Approximately 7.6% of U.S. adults identify as LGBT or something other than heterosexual, according to the most recent Gallup data. Applied to the ACS’s 2024 estimate of more than 2 million new cancer diagnoses annually, that translates to approximately 152,000 sexual and gender minority (SGM) people receiving a cancer diagnosis each year in the United States. That is a large population. It is also a population for which the evidence base is thin, clinical guidelines are largely unadapted, and routine care is frequently inadequate.

This is not a new observation. The National Institutes of Health formally designated sexual and gender minorities as a population experiencing health disparities for research purposes in 2016. The Institute of Medicine called for increased research investment in SGM health in 2011. A decade and a half later, the research infrastructure to support that work is only now beginning to reach the scale the problem requires.

What the Evidence Shows: LGBTQ+ Cancer Disparities Are Real and Understudied

The 2024 ACS Cancer Facts and Figures Special Section on Cancer in LGBTQ+ People is the most comprehensive synthesis of this evidence to date. Its findings point to disparities across three dimensions: higher cancer risk, lower screening uptake, and worse experiences of care.

Higher cancer risk driven by modifiable factors

LGBTQ+ individuals have higher rates of several modifiable cancer risk factors compared to heterosexual and cisgender populations. The disparities are not uniform across all subgroups, but the patterns are consistent enough to be clinically meaningful.

Tobacco use: LGBTQ+ individuals have higher rates of smoking than the general population. Tobacco is the leading preventable cause of cancer, responsible for at least 30% of all cancer deaths. Higher tobacco prevalence in LGBTQ+ communities is a downstream consequence of stress, social marginalization, and targeted marketing by the tobacco industry to LGBTQ+ communities over decades.

Alcohol use: Lesbian, gay, and bisexual individuals are more likely to engage in heavy alcohol consumption than heterosexual peers, according to the ACS report. Alcohol use increases risk for liver, esophageal, colorectal, oral, stomach, and breast cancers.

Excess body weight: Lesbian and bisexual individuals assigned female at birth are more likely to have excess body weight than their heterosexual counterparts, with lower rates of leisure-time physical activity contributing to the disparity. Excess weight is a risk factor in at least 12 types of cancer.

HIV status: Gay and bisexual men have substantially higher rates of HIV infection, and people living with HIV have elevated risk for multiple cancers, including non-Hodgkin lymphoma, Kaposi sarcoma, and anal cancer, as well as certain non-AIDS-defining cancers.

The ACS authors were careful to frame these risk factors as products of social and structural conditions, not inherent properties of LGBTQ+ identity. The minority stress model, which documents how chronic exposure to discrimination, stigma, and social marginalization produces downstream health consequences, is the framework that best explains these patterns.

Lower screening rates and later-stage diagnoses

The disparities are not limited to risk exposure. They extend to cancer detection.

At the 2024 ASCO Annual Meeting, researchers presented findings from a study of 817 LGBTQ+ cancer patients: 80% had not received appropriate cancer screening for their age. The reasons were not primarily attitudinal. They reflected structural barriers: the provider did not mention screening, the patient did not have a provider for routine care, and lack of insurance. Avoidance of healthcare settings due to prior experiences of discrimination was also a significant contributing factor.

NCI’s Cancer Currents Blog summarized the evidence clearly: there is consistent evidence that SGM people are less likely to seek care for possible cancer symptoms, and as a result their cancers may be diagnosed at more advanced stages. Later-stage diagnosis is one of the most powerful predictors of worse outcomes in most cancer types.

Worse experiences during cancer care

A 2025 study from the Moffitt Cancer Center published in JNCI Monographs analyzed real-world SOGI data collected at an NCI-designated comprehensive cancer center and found that SGM individuals with a history of cancer report significantly greater distress, relationship difficulties, substance use, dissatisfaction with cancer care, and lower quality of life compared with heterosexual and cisgender counterparts.

A 2023 study in JAMA Oncology examining breast cancer in sex and gender minority groups found disparities in diagnosis, treatment, and outcomes compared to cisgender women. And a 2025 review in PMC covering breast cancer disparities in LGBTQ+ communities concluded that disparities exist from screening through survivorship and lead to measurably worse outcomes.

The Root Cause: You Cannot Fix What You Cannot Measure

If there is a single structural problem behind LGBTQ+ cancer disparities, it is the routine failure to ask patients who they are.

Sexual orientation and gender identity (SOGI) data refers to the collection of patients’ sexual orientation and gender identity in clinical intake and electronic health records. Most health systems in the United States do not do this consistently or at all. When oncology teams do not know a patient is gay, bisexual, transgender, or nonbinary, they cannot screen for subgroup-specific risks, connect the patient to appropriate support services, or enroll them in research studies that could generate knowledge about their population.

The consequences are not merely administrative. A transgender woman who presents with breast symptoms may receive different clinical attention than a cisgender woman. A gay man’s partner may not be included in care conversations in the same way as a heterosexual spouse. A nonbinary patient’s need for survivorship support that accounts for their identity may simply not be addressed.

A 2025 JNCI Monographs paper on SOGI data collection in oncology described the problem directly: a standardized approach to collecting accurate SOGI data is critical to best serving LGBTQ+ patients’ cancer care needs, fully understanding the scale of disparities, and generating the research needed to address them. The paper called for best practices for SOGI collection and dissemination across cancer centers.

Why SOGI data collection is harder than it sounds, and why it is still the right target Healthcare providers sometimes resist SOGI data collection out of concern that patients will find the questions intrusive or that the data will be used inappropriately. The research does not support this concern. Multiple studies have shown that most patients, including LGBTQ+ patients, are willing to disclose SOGI information when asked in a respectful, standardized clinical context, and that they consider it important for their care. The barriers are primarily on the provider and system side, not the patient side. Implementation requires: standardized, validated questions in intake workflows (the “Do Ask, Do Tell” framework from The Fenway Institute); training staff in respectful, inclusive communication; integrating SOGI fields into electronic health record systems; and using the data for clinical decision support rather than collecting it and ignoring it. None of these steps are technically complex. They require institutional commitment.

What the Research Community Is Doing About It

The evidence base for LGBTQ+ cancer disparities has grown substantially in the past five years, but the research infrastructure to support it has lagged behind. Several developments are beginning to address that gap.

The Q Cancer Research Center

In Spring 2026, the American Cancer Society funded a new Cancer Health Research Center (CHERC) at the University of Rochester: the Q Cancer Research Center. It is designed as a national center without walls, meaning its scope extends beyond a single institution.

The Q Cancer Research Center’s funded projects specifically address three of the gaps identified above: improving the standardized collection of SOGI data in clinical settings, developing survivorship programs tailored to LGBTQ+ patients’ specific needs and identities, and training a new generation of researchers with expertise in LGBTQ+ cancer health equity. The center’s structure as a national collaborative rather than a site-specific program is designed to generate findings and tools that can be implemented broadly.

NCI investment in SGM cancer research

The National Cancer Institute has developed a dedicated funding opportunity for research on cancer care and outcomes in SGM cancer survivors, and launched the SGM Cancer CARE program to train 150 early-career investigators over five years. The first national conference dedicated to SGM cancer research was held in October 2023, with nearly 200 attendees, marking a recognition within the research community that this field needs its own infrastructure.

Growing clinical recognition

The American Society for Clinical Oncology (ASCO) has recognized SGM communities as a population experiencing health disparities and has increasingly incorporated SGM health equity into its conference programming and clinical guidance development. The Fenway Institute maintains the “Do Ask, Do Tell” SOGI data collection framework and training resources for clinical teams. The National LGBT Cancer Network provides patient navigation and provider education specifically focused on LGBTQ+ cancer care.

What This Means for Patients and Clinicians

For LGBTQ+ patients navigating cancer screening and care

The disparities documented in the research are real but they are not inevitable. They are products of structural barriers, not immutable characteristics of LGBTQ+ identity. Several resources exist specifically to support LGBTQ+ patients in cancer prevention and care:

The National LGBT Cancer Network provides education, advocacy, and referrals to inclusive cancer care providers
GLMA: Health Professionals Advancing LGBTQ+ Equality maintains a provider directory of LGBTQ-affirming healthcare professionals
The Fenway Institute is a clinical and research center with deep expertise in LGBTQ+ health, including cancer
NCI’s cancer screening resources provide evidence-based information on recommended screening by cancer type; discussions with any provider should account for individual anatomy and history, not assumed demographics

If you have experienced discrimination or inadequate care in oncology settings because of your sexual orientation or gender identity, that experience is well-documented and not isolated. Seeking a second opinion from a provider with LGBTQ+ health expertise is a reasonable step.

For oncology clinicians and care teams

The single most actionable change most clinical settings can make is implementing standardized SOGI data collection at intake. The Fenway Institute’s “Do Ask, Do Tell” resources provide validated question formats and implementation guidance. Collecting this data is not sufficient on its own; care teams need to use it to inform clinical conversations, support navigation to LGBTQ+-specific resources, and report it in ways that can be aggregated for research.

Survivorship care plans should explicitly address LGBTQ+ patients’ specific needs, including the intersection of gender-affirming hormone therapy with cancer treatment decisions, the mental health burden associated with minority stress, and the importance of including chosen family and partners in care conversations.

For related women’s health and cancer coverage on Health Evidence Digest, see our posts on the first approved immunotherapy for ovarian cancer, cervical cancer screening guidelines for 2026, and AI-supported mammography and the MASAI trial findings.

Sources

ACS 2024 LGBTQ+ Cancer Special Section: American Cancer Society. Cancer Facts and Figures 2024 Special Section: Cancer in People Who Identify as Lesbian, Gay, Bisexual, Transgender, and/or Queer. cancer.org.

ACS LGBTQ+ Report press release (2024): American Cancer Society Releases Pioneering LGBTQ+ Cancer Report. pressroom.cancer.org. May 2024.

NCI Cancer Currents LGBTQ+ disparities: Cancer Health Disparities Among LGBTQ+ People. cancer.gov. May 2024.

Moffitt SOGI data study (JNCI Monographs 2025): Zamani SA, Pérez-Morales J, et al. Sexual orientation and gender identity data reveals real-world cancer disparities among sexual and gender minorities at an NCI-Designated Comprehensive Cancer Center. JNCI Monographs. 2025;69:76-87. doi:10.1093/jncimonographs/lgaf017. PMC12268166.

SOGI data collection best practices (JNCI Monographs 2025): Developing, implementing, and disseminating best practices for SOGI collection among cancer patients. JNCI Monographs. 2025;69:96. doi:10.1093/jncimono/lgaf016.

ASCO 2024 LGBTQ+ screening abstract: Maingi S, Schabath MB, Dewald I, et al. Disparities uncovered: LGBTQ+ patients report on their cancer care journey. ASCO 2024. Abstract 1516.

Breast cancer LGBTQ+ disparities (JAMA Oncology 2023): Eckhert E et al. Breast cancer diagnosis, treatment, and outcomes of patients from sex and gender minority groups. JAMA Oncol. 2023;9(4):473-480.

Breast cancer LGBTQ+ review (PMC 2025): Breast Cancer Disparities in the LGBTQ+ Community. PMC12320750.

Gallup LGBTQ+ identification data: LGBT Identification in U.S. Ticks Up to 7.6%. Gallup.

Minority stress model reference: Meyer IH. Prejudice, Social Stress, and Mental Health in Lesbian, Gay, and Bisexual Populations. Psychol Bull. 2003.

Do Ask, Do Tell SOGI framework: The Fenway Institute. Do Ask, Do Tell.

ACS research grant programs: American Cancer Society Institutional Research Grants and CHERC Awards. cancer.org.

Patient resources: National LGBT Cancer Network | GLMA Provider Directory | The Fenway Institute | NCI Cancer Screening

Disclaimer: Health Evidence Digest provides general information about health research and cancer equity for educational purposes. This content is not a substitute for professional medical advice. Cancer screening and treatment decisions should be made in consultation with a qualified healthcare provider.

April 13, 2026

Once-Weekly Navepegritide Is Now FDA-Approved for Children With Achondroplasia. Here Is What the APPROACH Trial Data Actually Shows.

📌 The essentials On February 27, 2026, the FDA approved YUVIWEL (navepegritide, Ascendis Pharma) under the Accelerated Approval Program for increasing linear growth in children aged 2 years and older with achondroplasia with open epiphyses. This is the first and only once-weekly treatment for achondroplasia and the only approved therapy that provides continuous systemic CNP exposure over the weekly dosing interval. The clinical basis: The Phase 2b APPROACH randomized controlled trial (NCT05598320) published in JAMA Pediatrics (November 2025) showed annualized growth velocity (AGV) of 5.84 cm/year with navepegritide versus 3.88 cm/year with placebo (p less than 0.0001), a difference of nearly 2 cm/year additional growth. Accelerated approval context: continued approval may be contingent on confirmatory trials verifying long-term clinical benefit. AGV is the accepted surrogate endpoint; long-term height and functional outcomes are the subject of ongoing follow-up. How it compares: the only other approved therapy for achondroplasia is vosoritide (Voxzogo, BioMarin), approved in 2021, which requires daily injection. YUVIWEL is weekly. Neither has been compared head-to-head in a clinical trial. Rare Pediatric Disease Priority Review Voucher granted alongside this approval. Commercial availability: expected early Q2 2026.

Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in 15,000 to 40,000 live births worldwide. It is caused by a gain-of-function mutation in the FGFR3 gene that overactivates a signaling pathway limiting endochondral bone growth. For decades, treatment was supportive, focused on managing the complications of the condition rather than addressing its underlying biology. That began to change in 2021, when the FDA approved the first drug targeting the root cause of achondroplasia. On February 27, 2026, a second drug entered clinical use offering the same mechanistic approach with a meaningful practical difference: once-weekly dosing instead of once-daily.

YUVIWEL (navepegritide) was developed by Ascendis Pharma using their TransCon technology. Its FDA approval under the Accelerated Approval Program makes it the first and only once-weekly treatment for achondroplasia, supported by robust Phase 2b trial data published in JAMA Pediatrics and presented at major pediatric endocrinology meetings.

What Achondroplasia Is and Why It Extends Beyond Height

To understand what navepegritide does, it helps to understand what achondroplasia actually is, because the condition is more than a difference in stature.

Achondroplasia causes characteristic skeletal features including short stature with rhizomelic (proximal limb) shortening, enlarged head circumference with midface hypoplasia, exaggerated lumbar lordosis, and bowed legs. The average adult height in achondroplasia is approximately 4 feet 1 inch (125 cm) in women and 4 feet 4 inches (131 cm) in men. But height is one dimension of the condition’s impact.

Achondroplasia is a multisystem condition. Many affected individuals face:

Spinal cord compression at the foramen magnum, which can cause central apnea and is the leading cause of sudden death in infancy in achondroplasia
Spinal stenosis in adulthood, causing pain, weakness, and neurological symptoms
Obstructive sleep apnea, occurring in a majority of affected children
Recurrent otitis media and associated hearing loss due to midface hypoplasia
Varus deformity (bowing) of the lower extremities affecting mobility and joint health

This multisystem burden is why the pediatric orthopedic and skeletal dysplasia research community frames achondroplasia pharmacotherapy in terms of improving overall skeletal development, not simply maximizing height. The APPROACH trial endpoints reflect this: in addition to AGV, the trial measured tibial-femoral angle, mechanical axis deviation, fibula-to-tibia length ratio, and the Achondroplasia Child Experience Measure for physical functioning.

The Mechanism: CNP and the FGFR3 Pathway

The biology behind navepegritide requires understanding what the FGFR3 mutation actually does and how CNP counteracts it.

In normal bone growth, endochondral ossification converts cartilage to bone at growth plates. This process depends on chondrocyte (cartilage cell) proliferation and differentiation being maintained at the appropriate rate. FGFR3 (fibroblast growth factor receptor 3) normally acts as a brake on this process. In achondroplasia, the gain-of-function FGFR3 mutation overactivates this brake through the MAPK signaling pathway, suppressing chondrocyte proliferation and slowing bone elongation.

C-type natriuretic peptide (CNP) is a naturally occurring peptide that counteracts FGFR3-MAPK signaling. By activating its receptor (NPR-B) in chondrocytes, CNP inhibits the overactivated MAPK pathway, supporting more normal chondrocyte proliferation and therefore more normal bone growth. The therapeutic logic is to restore CNP-mediated inhibition of the overactive FGFR3 pathway.

Navepegritide is a CNP analog prodrug. “Prodrug” means it is administered in an inactive or slowly releasing form that is converted to active CNP in the body over time. Ascendis Pharma’s TransCon technology uses a hydrolytically cleavable linker to attach CNP to an inert carrier. After subcutaneous injection, the linker degrades slowly, releasing active CNP at a controlled, continuous rate over approximately seven days, matching the weekly dosing interval. This sustained release is the key pharmacological advance over vosoritide, which has a short half-life requiring daily injection to maintain therapeutic CNP exposure.

The APPROACH Trial: What the Evidence Shows

Trial design

The APPROACH trial (NCT05598320) was a Phase 2b, randomized, double-blind, placebo-controlled study enrolling 84 children aged 2 to 11 years with achondroplasia across seven countries. Participants were randomized 2:1 to receive navepegritide 100 μg/kg subcutaneously once weekly or placebo for 52 weeks, followed by a single-arm open-label extension (OLE) in which placebo-treated children crossed over to navepegritide.

The primary endpoint was annualized growth velocity (AGV) at week 52. Secondary endpoints included changes in skeletal proportionality measures (tibial-femoral angle, mechanical axis deviation, fibula-to-tibia length ratio) and the Achondroplasia Child Experience Measure for physical functioning.

52-week results

Endpoint	Navepegritide	Placebo	Significance
Annualized growth velocity (AGV)	5.84 cm/year	3.88 cm/year	p less than 0.0001
Difference in AGV (LS mean)	+1.96 cm/year	Reference	Statistically significant
Tibial-femoral angle	Improved	No improvement	Significant
Mechanical axis deviation	Improved	No improvement	Significant
Fibula-to-tibia length ratio	Improved	No improvement	Significant
Physical functioning (ACH-CPM)	Improved	No improvement	Significant
Safety: grade 3 or higher AEs related to drug	None reported	—	Favorable

Source: Savarirayan R et al. JAMA Pediatrics. 2025;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771. PMC12624480.

The nearly 2 cm/year additional AGV over placebo is the headline number. To contextualize it: untreated children with achondroplasia typically grow at rates substantially below age-matched peers without the condition. Adding nearly 2 cm/year of growth velocity, across years of treatment, could translate to several centimeters of additional stature by the end of linear growth, though height is a secondary consideration given the bone proportionality and functional improvements also observed.

The improvements in tibial-femoral angle and mechanical axis deviation are clinically significant beyond their contribution to height. These measurements reflect the degree of lower limb bowing that is common in achondroplasia and contributes to gait abnormalities, knee pain, and long-term joint health. Improving these parameters addresses functional and structural aspects of the condition, not just growth velocity.

The Achondroplasia Child Experience Measure for physical functioning is a validated patient-reported outcome instrument assessing how children experience the physical limitations of achondroplasia in daily activities. Its improvement alongside the growth and skeletal endpoints indicates that the trial captured changes meaningful to the children themselves, not only measurements observable on radiographs.

Two-year data (May 2026 update)

In May 2026, Ascendis presented two-year APPROACH trial data showing pronounced gains specifically in children aged 5 years and older. In this subgroup, navepegritide produced AGV of 5.84 cm/year (observed mean) versus 3.88 cm/year on placebo over the initial 52 weeks, with durable benefit sustained through the open-label extension. The company also presented data from the combination navepegritide plus lonapegsomatropin (once-weekly growth hormone) program, which showed mean AGV of 8.80 cm/year in treatment-naive children and exceeded the 97th-percentile AGV of average-stature children after 52 weeks, though this combination is investigational and not yet approved.

Accelerated Approval: What It Means Here

The FDA granted YUVIWEL approval under the Accelerated Approval Program, which allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit. The surrogate endpoint for YUVIWEL is annualized growth velocity.

Continued approval is contingent on verification of clinical benefit in confirmatory trials. Ascendis is conducting confirmatory long-term studies evaluating final adult height and clinical functional outcomes. This is standard practice for accelerated approvals in rare pediatric diseases and does not mean the drug’s efficacy is uncertain; it means that the FDA has determined the available evidence is sufficient for approval now while longer-term confirmatory data is generated.

YUVIWEL vs. vosoritide (Voxzogo): how they compare Vosoritide (Voxzogo, BioMarin) was the first disease-targeting drug approved for achondroplasia, in August 2021. It is a CNP analog but not a prodrug: it requires daily subcutaneous injection because its active form degrades quickly in the body. Navepegritide is a prodrug using TransCon technology to achieve weekly dosing through sustained release, providing continuous CNP exposure over the dosing interval rather than daily peaks and troughs. Both target the same CNP-FGFR3 pathway. Neither has been directly compared in a head-to-head randomized trial. The evidence for vosoritide’s efficacy comes from the pivotal ACH-003 trial, which showed a difference of 1.57 cm/year in AGV versus placebo. The APPROACH trial showed a 1.96 cm/year difference for navepegritide versus placebo. Cross-trial comparisons are unreliable and should not be used to conclude one drug is superior. The clinically relevant difference for families is dosing schedule: once-weekly versus once-daily injection. For young children, the reduction in injection frequency is a meaningful quality-of-life consideration.

Safety Profile

The safety profile of navepegritide in the APPROACH trial was favorable, with no grade 3 or higher adverse events attributed to the drug. The most common adverse events were consistent with the expected profile of a subcutaneous injection therapy in children:

Injection site reactions (most common, typically mild and transient)
Headache
Fever
Vomiting
Upper respiratory symptoms

No new safety signals were identified in the extended follow-up period. The full prescribing information includes complete safety data and monitoring recommendations.

Regulatory Designations

YUVIWEL received multiple FDA designations supporting its development:

Accelerated Approval
Rare Pediatric Disease designation (and Rare Pediatric Disease Priority Review Voucher granted alongside approval)
Orphan Drug designation
Breakthrough Therapy designation

As discussed in our post on the first gene therapy for genetic deafness, the Rare Pediatric Disease Priority Review Voucher is a transferable incentive granted upon approval of therapies for rare pediatric conditions. It can be used by Ascendis or sold to another pharmaceutical company to accelerate a different drug’s FDA review, and has market value in the hundreds of millions of dollars. The voucher program exists specifically to incentivize development of treatments for conditions affecting small pediatric populations where commercial markets alone would not support development costs.

What This Approval Means for Families

For a child aged 2 to 11 years with achondroplasia and open growth plates, YUVIWEL is now an FDA-approved treatment option. The practical question for most families will be a conversation with a pediatric endocrinologist or geneticist at a center specializing in skeletal dysplasia about whether navepegritide or vosoritide is the right choice for their child’s specific situation.

Key considerations include the child’s current growth trajectory, whether they are already on vosoritide, family preference for injection frequency, and access and insurance coverage. YUVIWEL is expected to be available through commercial channels beginning early Q2 2026.

For families with children being managed at a skeletal dysplasia center, this conversation should be initiated with the treating team. For families who do not have access to specialized skeletal dysplasia care, the Achondroplasia & Hypochondroplasia Alliance, Little People of America, and the National Organization for Rare Disorders (NORD) maintain physician referral resources, patient community networks, and current information on treatment options.

ClinicalTrials.gov lists ongoing navepegritide trials including the adolescent trial (NCT06732895) for ages 12 to 18 and the combination lonapegsomatropin trial, for families interested in investigational options beyond the current approval.

For related coverage of rare pediatric disease FDA approvals, see our posts on the first gene therapy for genetic deafness approved under the Rare Pediatric Disease PRV program and the UX111 gene therapy for Sanfilippo syndrome now under FDA review.

Sources

Ascendis Pharma FDA approval press release: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older. GlobeNewswire. February 27, 2026.

APPROACH trial primary publication: Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatrics. 2025;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771. PMC12624480.

APPROACH trial registration (Phase 2b): NCT05598320. ClinicalTrials.gov.

Two-year APPROACH data (May 2026): New 2-Year Data from Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged 5 Years. GlobeNewswire. May 6, 2026.

Pediatric Endocrine Society clinical review: Navepegritide (Yuviwel) for Children with Achondroplasia: New Drugs and Therapeutics. pedsendo.org. March 2026.

Contemporary Pediatrics approval coverage: FDA Issues Historic Approval for Navepegritide in Achondroplasia. contemporarypediatrics.com. 2026.

Combination therapy data (HCPLive): Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial. hcplive.com. February 2026.

Adolescent trial registration: NCT06732895. ClinicalTrials.gov.

Vosoritide FDA approval: FDA approves vosoritide for achondroplasia. FDA.gov. August 2021.

YUVIWEL prescribing information: YUVIWEL (navepegritide) full prescribing information. accessdata.fda.gov.

Achondroplasia NORD overview: Achondroplasia. NORD.

NIH GARD achondroplasia: Achondroplasia. rarediseases.info.nih.gov.

CNP biology reference: C-type natriuretic peptide and bone growth. PMC3482906.

Endochondral ossification reference: Endochondral Ossification. StatPearls. NCBI.

Accelerated Approval pathway: Accelerated Approval Program. FDA.gov.

Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

Patient resources: Achondroplasia & Hypochondroplasia Alliance | Little People of America | NORD: Achondroplasia | ClinicalTrials.gov: navepegritide

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about treatment for children with achondroplasia should be made in close consultation with a pediatric endocrinologist, geneticist, or specialist in skeletal dysplasia familiar with the child’s individual growth history and clinical circumstances.

April 12, 2026

The FDA Just Added a New Warning to All Carbidopa/Levodopa Parkinson’s Medications. Here Is What It Says and Why It Matters.

⚠️ Key Safety Summary On March 20, 2026, the FDA issued a Drug Safety Communication requiring new warnings on all carbidopa/levodopa-containing medications for Parkinson’s disease, addressing the risk of vitamin B6 (pyridoxine) deficiency and associated seizures. What the FDA found: 14 confirmed cases of seizures linked to vitamin B6 deficiency in patients on carbidopa/levodopa products, including 2 fatalities. All cases involved levodopa doses exceeding 1,000 mg daily. Latency periods ranged from 23 to 132 months, meaning the problem can develop years into treatment. The seizures are clinically distinctive: they do not respond to standard anti-seizure medications but resolve after vitamin B6 supplementation. In 9 of 9 patients who received B6 supplementation, seizures fully resolved. In some cases, progression to status epilepticus was observed before the diagnosis was made. What is now required: healthcare professionals must evaluate baseline vitamin B6 levels before starting treatment, monitor periodically during treatment, and supplement as needed. If you or someone you care for is on a carbidopa/levodopa medication: do not stop the medication without medical guidance. Report new symptoms (seizures, confusion, numbness, tingling) to your prescriber promptly.

Parkinson’s disease affects approximately 1 million Americans and is the second most common neurodegenerative condition in the United States. The cornerstone of pharmacological management is levodopa, which the brain converts to dopamine to compensate for the progressive loss of dopamine-producing neurons. Levodopa is almost always combined with carbidopa, which prevents levodopa from being metabolized in the bloodstream before it reaches the brain, allowing lower and more effective doses.

These medications work well. Many patients take them for years or decades. But a drug safety communication issued by the FDA on March 20, 2026 has established, for the first time with a formal labeling requirement, that the same mechanism that makes carbidopa/levodopa effective is also depleting vitamin B6, and that this depletion can, in some patients, cause seizures that clinicians may not immediately recognize as B6-related.

What the FDA Found: 14 Cases, 2 Deaths, and a Seizure Type That Resists Standard Treatment

The FDA’s safety review identified 14 cases of seizures linked to vitamin B6 deficiency in patients using carbidopa/levodopa products. Thirteen were postmarketing reports submitted to the FDA Adverse Event Reporting System (FAERS) database; one was identified in the medical literature.

Because the FDA notes that its review relied on spontaneous case reports and that similar cases may exist unreported, the 14 confirmed cases likely underestimate the true incidence.

Key characteristics of the 14 cases:

Feature	Detail
Total confirmed cases	14
All cases: levodopa dose	Above 1,000 mg daily in every case
Higher doses (above 1,500 mg)	Associated with shorter time to deficiency development
Latency period (treatment start to seizure onset)	23 to 132 months
Seizure type	Focal onset seizures with secondary generalization; some progressed to status epilepticus
Response to standard anti-seizure medications	Did not respond in the majority of cases
Response to vitamin B6 supplementation	9 of 9 treated patients had complete resolution
Fatalities	2, both with documented low vitamin B6 levels and poorly controlled seizures
Formulations involved	Oral tablets and enteral suspension
Cases involving Stalevo or Vyalev	None confirmed, but biological plausibility supports similar risk

Source: FDA Drug Safety Communication, March 20, 2026.

The status epilepticus finding is the most urgent clinical detail

The FDA communication notes that progression to status epilepticus was observed in some of the reported cases. Status epilepticus is a neurological emergency, defined as a seizure lasting more than five minutes or two or more seizures without full recovery of consciousness between them. It carries significant risk of brain injury and death if not treated rapidly. In the context of this safety communication, the critical clinical implication is that if a patient on carbidopa/levodopa presents with new-onset seizures that do not respond to conventional anti-seizure medications, vitamin B6 deficiency should be in the differential diagnosis immediately, not as a last resort.

The seizure pattern described is consistent with vitamin B6-dependent epilepsy: focal onset seizures with secondary generalization that resist standard anticonvulsants and resolve with pyridoxine. This pattern has a known biochemical mechanism.

The supporting evidence for B6 deficiency in these cases

Beyond the seizures themselves, the FDA review found additional laboratory and clinical evidence of vitamin B6 deficiency in the reviewed cases:

Elevated homocysteine levels in four cases (B6 is required for homocysteine metabolism; deficiency causes it to accumulate)
Microcytic or normocytic anemia in three cases (B6 is required for heme synthesis)
Neuropsychiatric symptoms in four cases

This multi-system evidence of B6 deficiency strengthens the FDA’s conclusion that “there is reasonable evidence of a causal association between drug products containing carbidopa/levodopa and vitamin B6 deficiency-associated seizures.”

Why Carbidopa/Levodopa Depletes Vitamin B6: The Mechanism

Understanding the biochemical basis of this safety signal helps explain both why it is real and why it has been underrecognized.

Vitamin B6 (pyridoxine) is a water-soluble vitamin with a critical role in over 100 enzymatic reactions in the body, particularly in amino acid metabolism and neurotransmitter synthesis. Its active form, pyridoxal-5′-phosphate (PLP), is the biologically active cofactor.

Carbidopa/levodopa depletes B6 through two mechanisms operating simultaneously:

First: The conversion of levodopa to dopamine (and its subsequent metabolism) consumes PLP as a cofactor. At higher levodopa doses, this ongoing metabolic consumption exceeds normal dietary intake and tissue stores.

Second: Carbidopa itself binds to and inactivates pyridoxal phosphate. This is not a side effect unique to therapeutic use. The structural interaction between carbidopa and PLP is well-characterized biochemically, and it was the reason that earlier levodopa formulations without carbidopa actually caused peripheral B6 depletion through a somewhat different pathway.

The combined effect is a functional reduction in available B6 that compounds over time at higher doses. The long latency period (23 to 132 months) reflects this gradual depletion dynamic: it takes time for dietary intake and tissue stores to be overwhelmed.

What Products Are Affected

The new warning requirement applies to all drug products containing carbidopa and levodopa. These include:

Brand name	Components	Formulation
Sinemet, Sinemet CR	Carbidopa/levodopa	Oral tablets (immediate and controlled release)
Rytary	Carbidopa/levodopa	Oral extended-release capsules
Dhivy	Carbidopa/levodopa	Oral tablets
Crexont	Carbidopa/levodopa	Oral extended-release capsules
Duopa	Carbidopa/levodopa	Enteral suspension (continuous infusion)
Stalevo	Carbidopa/levodopa/entacapone	Oral tablets
Vyalev	Foscarbidopa/foslevodopa	Subcutaneous infusion

No confirmed cases of B6-deficiency seizures were found with Stalevo or Vyalev, which the FDA attributes to lower usage patterns, more recent approval dates, and different dosing requirements. However, the FDA explicitly states that biological plausibility supports similar risk across all formulations, noting that vitamin B6 deficiency was observed in the clinical trials for the injectable product. The warning applies to all formulations.

For Patients and Caregivers

Do not stop your medication without speaking to your neurologist or prescriber first

Carbidopa/levodopa is essential for managing Parkinson’s symptoms. Stopping abruptly can cause serious problems including a Parkinson’s crisis (sudden, severe worsening of symptoms), and in rare cases, a potentially life-threatening condition called neuroleptic malignant-like syndrome from abrupt withdrawal. The solution to B6 depletion is monitoring and supplementation, not stopping the medication.

What to watch for and report to your doctor immediately

Contact your prescriber promptly if you experience any of the following:

New or unexplained seizures of any kind
Confusion or worsening cognitive symptoms
Depression that seems different from your baseline
Numbness, tingling, sharp pains, or weakness in the hands, feet, or limbs
Mouth sores, inflammation of the tongue or lips, or skin changes
Persistent fatigue

If a seizure occurs and does not respond to emergency anti-seizure treatment, inform emergency responders and hospital staff that you are taking carbidopa/levodopa and that vitamin B6 deficiency-associated seizures should be considered. The seizures described in the FDA cases did not respond to conventional anticonvulsants but resolved with B6 supplementation.

Ask your provider about monitoring

Based on the new FDA warning, your prescriber should now:

Check your vitamin B6 level before starting or continuing treatment (particularly if you have been on levodopa for a long time or are on high doses)
Recheck B6 levels periodically during treatment
Consider whether vitamin B6 supplementation is appropriate for your situation

Do not self-supplement with high-dose B6 without medical guidance. While standard dietary doses of B6 are safe, high-dose pyridoxine supplementation (above 50 to 100 mg per day for extended periods) carries its own risk of peripheral neuropathy and should be managed by your provider.

Resources for people living with Parkinson’s disease

The Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research both maintain current patient-facing information on Parkinson’s medications, including updates on drug safety communications. The FDA’s safety communication page is updated as new information becomes available.

For Healthcare Professionals

The FDA’s new labeling requirement translates to the following clinical actions:

When	Action
Before starting carbidopa/levodopa	Evaluate baseline vitamin B6 (pyridoxine) and PLP levels
Periodically during treatment	Recheck B6 levels, frequency guided by dose and clinical status
If new symptoms appear	Evaluate B6 levels promptly regardless of time on therapy
If seizures occur	Recognize that B6 deficiency-associated seizures do not respond to standard anticonvulsants; vitamin B6 administration is the treatment
When titrating to doses above 1,000 mg levodopa	Higher vigilance warranted; doses above 1,500 mg levodopa associated with shorter time to deficiency
If adding anti-seizure medications	Be aware that select anticonvulsants can worsen B6 deficiency

The seizure type is distinctive and should be recognized: focal onset with secondary generalization, consistent with pyridoxine-dependent epilepsy, unresponsive to conventional anticonvulsants, and resolving with B6 administration. Elevated homocysteine, microcytic or normocytic anemia, and neuropsychiatric symptoms are supporting laboratory findings that can help confirm the diagnosis when seizures occur in the context of carbidopa/levodopa use.

Reporting Adverse Events

Patients and healthcare professionals should report adverse events related to carbidopa/levodopa products to the FDA MedWatch program online at fda.gov/safety/medwatch or by calling 1-800-332-1088. Reporting contributes to the pharmacovigilance database that identifies safety signals like this one. The FDA’s 14-case dataset almost certainly undercounts the true incidence of this adverse effect; reporting by clinicians who encounter it helps the agency characterize the full scope.

For related coverage of drug safety communications and post-market safety monitoring on Health Evidence Digest, see our post on the Tavneos (avacopan) serious liver injury warning and what it means when the FDA and a manufacturer disagree about risk and our analysis of why the FDA required post-marketing studies for Foundayo after its accelerated approval.

Sources

FDA Drug Safety Communication (primary source): FDA Is Requiring Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products Containing Carbidopa/Levodopa. March 20, 2026. fda.gov.

FDA DSC PDF: Drug Safety Communication PDF. fda.gov/media/191605.

FAERS reporting system: Questions and Answers: FDA’s Adverse Event Reporting System. fda.gov.

Vitamin B6 (pyridoxine) overview: Vitamin B6: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements.

Homocysteine and B6: Homocysteine. StatPearls. NCBI.

Status epilepticus: Status Epilepticus. StatPearls. NCBI.

Parkinson’s disease overview: Parkinson’s Disease. NINDS.

Levodopa withdrawal syndrome: Neuroleptic Malignant Syndrome and Parkinsonism-Hyperpyrexia. StatPearls. NCBI.

MedWatch reporting: FDA MedWatch. fda.gov/safety/medwatch.

Patient resources: Parkinson’s Foundation | Michael J. Fox Foundation

Disclaimer: Health Evidence Digest provides general information about FDA drug safety communications and health research for educational purposes. This content is not a substitute for professional medical advice. Patients taking carbidopa/levodopa-containing medications should not discontinue treatment without consulting their neurologist or prescribing clinician. Report new symptoms to your healthcare provider.

April 11, 2026

The FDA Rejected Replimune’s RP1 for Melanoma. Here Is Exactly Why, and What Has to Happen Next.

The essentials: On April 10, 2026, the FDA issued a Complete Response Letter (CRL) to Replimune for BLA 125827, its application for vusolimogene oderparepvec (RP1, also known as Vusolimogene oderparepvec, brand name RP1) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on prior PD-1-based therapy. The CRL is not a final rejection. It identifies deficiencies Replimune must address before the application can be reconsidered. The FDA’s concerns are entirely evidentiary, not about safety. The core problem: the pivotal evidence came from a single-arm Phase 2 study (RPL-001-16), which the FDA had previously told Replimune was insufficient to support approval. Without a randomized comparator, the agency could not determine whether observed tumor responses were attributable to RP1, to nivolumab, or to patient-specific factors. The path forward: the FDA requires adequate and well-controlled randomized trials demonstrating RP1’s independent contribution to clinical benefit. Replimune may request a Type A meeting with the FDA to discuss whether modifications to the ongoing IGNYTE-3 Phase 3 trial (NCT05765994) could address the requirements.

Unresectable melanoma that has progressed after checkpoint inhibitor therapy is one of the hardest clinical scenarios in oncology. PD-1 inhibitors like pembrolizumab and nivolumab transformed the treatment of metastatic melanoma beginning in 2014, extending survival for patients who previously had very limited options. But when melanoma progresses on those drugs, the question of what comes next has no clear answer. The approved options are limited, the responses are modest, and the disease is often aggressive by the time it reaches that stage.

Vusolimogene oderparepvec (RP1) is an oncolytic herpes simplex virus, an engineered virus designed to selectively infect and kill tumor cells while simultaneously triggering a systemic immune response. It was specifically developed to work in combination with checkpoint inhibitors and showed promising results in early-phase testing. Replimune submitted a Biologics License Application (BLA) based on Phase 2 data in combination with nivolumab.

On April 10, 2026, the FDA responded with a Complete Response Letter. The decision does not close the door on RP1. It identifies, in specific and instructive detail, exactly what the clinical evidence package was missing and what is required to proceed.

What Oncolytic Immunotherapy Is and Why RP1 Is Interesting

To understand what Replimune was trying to do, and why the regulatory challenge is real rather than arbitrary, it helps to understand the mechanism of oncolytic virotherapy.

Oncolytic viruses are engineered to selectively replicate inside tumor cells, causing them to burst and die, while largely sparing normal tissue. The death of those tumor cells releases antigens and danger signals that can alert the immune system to the presence of cancer. In theory, an oncolytic virus can convert a “cold” tumor, one with low immune infiltration and low response to checkpoint inhibitors, into a “hot” one where the immune system actively attacks the cancer.

RP1 is engineered from herpes simplex virus type 1 (HSV-1) with two modifications designed to enhance its therapeutic profile: deletion of the ICP34.5 gene to reduce neurovirulence and enhance tumor selectivity, and insertion of a GALV-GP R(-) fusogenic membrane glycoprotein that causes infected cells to fuse with neighboring cells, amplifying tumor cell death and antigen release. This fusogenic enhancement is what distinguishes RP1 from talimogene laherparepvec (T-VEC, Imlygic), the only previously approved oncolytic virus for melanoma, which does not carry this feature.

RP1 is administered by direct injection into tumor lesions (intratumoral injection). The proposed mechanism of clinical benefit involves both local tumor destruction at injected lesions and systemic immune activation that could, in principle, attack non-injected lesions and metastatic sites. That systemic effect is the central clinical and regulatory question: does injecting a virus into accessible tumors produce meaningful benefit throughout the body, and can a clinical trial reliably detect and attribute that benefit?

What the RPL-001-16 Trial Showed and Why It Was Not Enough

The pivotal evidence for the BLA came from RPL-001-16 (NCT03767348), a Phase 2 single-arm study evaluating RP1 plus nivolumab in patients with advanced cutaneous melanoma. The trial enrolled patients whose disease had progressed on prior PD-1 therapy, exactly the patient population with the highest unmet need in this disease.

In the Phase 2 data, the combination showed an objective response rate that generated initial enthusiasm in the oncology community. However, the FDA’s concern was not primarily about the magnitude of the responses. It was about whether the study design allowed any reliable conclusion about what caused them.

The FDA had communicated to Replimune prior to BLA submission that a single-arm trial in this combination setting was insufficient to demonstrate RP1’s contribution to clinical benefit. Replimune proceeded with the BLA nonetheless, apparently believing the strength of the data could overcome the design limitation.

It could not.

Why the FDA Issued the CRL: Four Specific Problems

1. The study design could not isolate RP1’s contribution

The fundamental problem with a single-arm trial combining RP1 with nivolumab is that nivolumab has established activity in melanoma. When a trial shows responses in patients receiving a known-active drug plus a new drug, with no control arm receiving the known-active drug alone, it is impossible to determine how much of the response came from the new drug. The FDA had been explicit that this design flaw was fatal to the application before it was submitted. A randomized trial comparing RP1 plus nivolumab versus nivolumab alone would allow direct attribution of incremental benefit to RP1.

2. The study population was too heterogeneous

Patients enrolled in RPL-001-16 varied substantially in prior treatments received, disease burden, lesion characteristics, and performance status. This variability made any cross-trial comparison unreliable and prevented meaningful benchmarking against external data. When a study is highly heterogeneous in ways not controlled by randomization, the results reflect the characteristics of who happened to be enrolled as much as the effects of the drug being studied.

3. Response assessments were uncertain and potentially confounded

The FDA identified multiple specific methodological issues that could artificially inflate the observed response rate:

Non-injected lesion problem: Many patients who showed an overall response did not have measurable non-injected target lesions. Since RP1 is injected directly into accessible tumors, any responses in those directly injected lesions could reflect local tumor destruction by the virus rather than systemic immune activation. If the drug’s value lies in producing systemic benefit beyond the injection site, the evidence needs to show response in tumors the drug never touched. In many cases, it could not.

Re-injection timing: Some patients received additional RP1 injections after new or enlarging lesions appeared. Under standard RECIST response criteria, new lesions or tumor enlargement typically counts as progression. Injecting the drug into new lesions and then observing their shrinkage can look like a response while obscuring what is actually a progressive disease pattern.

Surgical excisions and biopsies: Several patients underwent surgical removal or biopsy of lesions during the trial. These procedures can reduce measurable tumor burden in ways that are indistinguishable from drug-induced tumor shrinkage on imaging, inflating apparent response rates.

Local rather than central pathology review: Response assessments were performed by local investigators rather than a blinded central review committee. Local review is more susceptible to unconscious bias and inconsistency in applying response criteria than independent centralized review.

These factors collectively undermined the reliability of the reported objective response rate and duration of response as measures of true drug effect.

4. Supplemental data from the RP1-104 study were insufficient

Replimune attempted to support the BLA with additional data from an ongoing randomized Phase 2/3 study (RP1-104). However, the FDA found that only a small fraction of the planned study population had been treated at the time of submission, the data lacked independent review, the duration of response data were immature, and there was no prespecified statistical plan for the progression-free survival endpoint. The FDA concluded that these early, exploratory findings from RP1-104 could not compensate for the fundamental deficiencies in the pivotal RPL-001-16 study.

What the Field of Oncolytic Immunotherapy Needs to Learn From This

The RP1 CRL is instructive beyond Replimune specifically. It articulates the evidentiary standards the FDA will apply to intratumoral therapies combined with checkpoint inhibitors, and those standards were not invented for this application. They reflect well-established principles of clinical trial design.

Single-arm trials cannot isolate combination drug contributions. When a novel therapy is combined with an agent that already has proven activity in the indication, a randomized trial with an appropriate comparator arm is not optional. This principle applies across oncology, not just to oncolytic viruses.

Intratumoral therapies must demonstrate systemic activity. The clinical value proposition of an oncolytic virus is not that it kills directly injected tumors. Surgery can do that. The value proposition is that it triggers systemic immune responses that benefit the whole patient. Evidence of that systemic benefit requires trial designs that can detect and attribute responses in non-injected disease sites.

Methodological details matter enormously in solid tumor oncology. Re-injection timing, lesion selection for target measurement, the role of concurrent procedures, and the choice of central versus local review are not administrative details. They are scientifically material choices that determine whether a response rate number means what it appears to mean.

The FDA’s prior communications are not suggestions. Replimune knew before submitting its BLA that the agency had reservations about the single-arm design. Proceeding without addressing that concern was a high-risk regulatory strategy that did not succeed. The FDA’s pre-BLA communications and Type B meetings are the appropriate time to reach agreement on whether an evidentiary package is sufficient.

The Path Forward: IGNYTE-3

Replimune has an ongoing Phase 3 trial that may ultimately provide the evidence the FDA requires. The IGNYTE-3 trial (NCT05765994) is a randomized, controlled study designed specifically to address the gap identified in RPL-001-16. The FDA has indicated that Replimune may request a meeting to discuss whether modifications to IGNYTE-3 or additional studies could meet the requirements outlined in the CRL.

What that trial will need to show, based on the CRL’s specific feedback, is a clear, independently reviewed, randomized demonstration that the combination of RP1 plus nivolumab produces greater clinical benefit than nivolumab alone in patients with unresectable advanced melanoma that has progressed on prior PD-1 therapy. The primary endpoint will need to capture systemic activity, not just responses at injected sites, and the trial design will need to prevent the confounding issues that undermined RPL-001-16.

The timeline for such a result is measured in years, not months. Until IGNYTE-3 or another adequate study reports, RP1 remains investigational for this indication.

What This Means for Patients With Advanced Melanoma

For patients with unresectable melanoma that has progressed on PD-1 therapy, RP1 is not currently an approved treatment option. The CRL means it will remain investigational until adequate trial evidence is generated and reviewed.

The approved options for melanoma after progression on PD-1 therapy are limited and depend on individual patient factors including BRAF mutation status, prior treatment history, and performance status. Current options include:

BRAF/MEK inhibitor combinations (dabrafenib plus trametinib, vemurafenib plus cobimetinib, encorafenib plus binimetinib) for patients with BRAF V600 mutations
Ipilimumab (Yervoy) alone or in combination with nivolumab in appropriate patients
Talimogene laherparepvec (T-VEC, Imlygic) for unresectable local or regional disease, the only currently approved oncolytic therapy in melanoma
Clinical trial enrollment

For patients with unresectable advanced melanoma, especially those who have progressed on checkpoint inhibitor therapy, clinical trial enrollment is not a last resort. It is often the best option to access novel therapies in development. The IGNYTE-3 trial may have open enrollment sites. Additional clinical trial options can be searched at ClinicalTrials.gov.

The Melanoma Research Foundation and the Skin Cancer Foundation both maintain current information on melanoma treatment options and clinical trial resources.

For related coverage of how the FDA evaluates clinical evidence and what happens when that evidence is found insufficient, see our post on the camizestrant ODAC vote and what it reveals about ctDNA-guided treatment strategies and our analysis of pembrolizumab becoming the first approved immunotherapy for ovarian cancer to understand what a successful immunotherapy approval requires.

Sources

Complete Response Letter (primary source): CRL BLA125827 April 10, 2026. open.fda.gov.

Replimune press release: Replimune Announces Receipt of Complete Response Letter from FDA for RP1 (Vusolimogene Oderparepvec) BLA. Replimune. April 2026.

IGNYTE-3 Phase 3 trial: NCT05765994. ClinicalTrials.gov.

RPL-001-16 Phase 2 trial: NCT03767348. ClinicalTrials.gov.

Oncolytic virus immunotherapy review: Oncolytic Viruses: A New Class of Immunotherapy Agents. PMC8709598.

T-VEC FDA approval: FDA approves talimogene laherparepvec for melanoma. FDA.gov.

Nivolumab melanoma approval: FDA approves nivolumab for melanoma. FDA.gov.

RECIST criteria: New Response Evaluation Criteria in Solid Tumours (RECIST). PMC3107543.

PD-1 inhibitors overview: Checkpoint Inhibitors. StatPearls. NCBI.

Complete Response Letter explained: Complete Response Letter. FDA.gov.

NCCN melanoma guidelines: Melanoma Cutaneous: Clinical Practice Guidelines. NCCN.

BRAF inhibitors: BRAF Inhibitors. cancer.gov.

Melanoma cancer overview: Advanced Melanoma Treatment. American Cancer Society.

Patient resources: Melanoma Research Foundation | Skin Cancer Foundation | ClinicalTrials.gov: melanoma oncolytic

Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. RP1 (vusolimogene oderparepvec) is not currently FDA-approved for any indication. Treatment decisions for advanced or metastatic melanoma should be made in consultation with a qualified oncologist experienced in melanoma and immunotherapy.

April 10, 2026

The First Oral IL-23 Receptor Blocker for Psoriasis Is FDA-Approved. Here Is What the ICONIC Trial Data Actually Shows.

The essentials: On March 18, 2026, the FDA approved ICOTYDE (icotrokinra, Johnson & Johnson) for the treatment of moderate to severe plaque psoriasis in adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. What makes it mechanistically distinctive: icotrokinra is the first oral peptide that directly blocks the IL-23 receptor, not the IL-23 ligand. All currently approved IL-23-targeting biologics (guselkumab, risankizumab, tildrakizumab) are monoclonal antibodies targeting the IL-23 cytokine itself. Icotrokinra works at the receptor level, introducing a distinct pharmacological approach in an established mechanism. How it is taken: one 200 mg tablet once daily, taken with water upon waking, at least 30 minutes before eating. May be dispersed in water for patients who have difficulty swallowing tablets. Who it is approved for: adults and adolescents aged 12 and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. The clinical basis: the Phase 3 ICONIC clinical development program across five randomized controlled trials enrolling more than 2,500 patients. Key efficacy numbers at week 16 across trials: IGA 0/1 (clear or almost clear skin) approximately 65 to 70%; PASI 90 approximately 50 to 57%. In head-to-head comparisons, icotrokinra showed superiority to deucravacitinib (Sotyktu) on both primary endpoints. At 52 weeks, complete skin clearance (PASI 100) rates increased to 48 to 49% in two pivotal studies.

Plaque psoriasis is among the most common immune-mediated skin conditions in the world, affecting more than 125 million people globally. It is not primarily a cosmetic problem. The chronic inflammation that drives the characteristic plaques, scaling, and itch also carries systemic consequences: psoriatic arthritis develops in up to 30% of patients, and individuals with moderate to severe disease have elevated cardiovascular risk, increased rates of depression and anxiety, and substantially reduced quality of life.

The treatment landscape for moderate to severe plaque psoriasis transformed with the arrival of biologics targeting the IL-17 and IL-23 pathways in the 2010s and 2020s. These injectable therapies produce very high rates of skin clearance but require subcutaneous or intravenous administration, carrying an injection burden that affects adherence for some patients. The oral options in this space have been limited: apremilast (Otezla) is a PDE4 inhibitor with more modest efficacy than IL-17 or IL-23 biologics, and deucravacitinib (Sotyktu) targets TYK2 and has shown meaningful but not biologic-comparable clearance rates.

ICOTYDE (icotrokinra), approved March 18, 2026, enters this landscape as the first oral therapy targeting the IL-23 receptor directly. The efficacy data from the ICONIC program puts it in a different category from prior oral options and, on some measures, in range of biologic-level responses, in a once-daily pill.

What Icotrokinra Is and How It Works

IL-23 (interleukin-23) is a cytokine that plays a central role in the inflammatory cascade driving plaque psoriasis. It activates and sustains Th17 cells, the immune cell population that produces IL-17, the downstream cytokine directly responsible for much of the skin inflammation in psoriasis. Blocking IL-23 at any point in this pathway reduces Th17 activation and downstream inflammation.

Existing IL-23-targeting biologics work by binding to the p19 subunit of the IL-23 cytokine itself, preventing it from activating its receptor. Icotrokinra takes a different approach: it is an oral peptide that binds directly to the IL-23 receptor (IL-23R) on the surface of immune cells, blocking the receptor from receiving the IL-23 signal regardless of how much IL-23 is present. This is mechanistically analogous to blocking the lock rather than confiscating the key.

The ability to deliver this level of receptor-targeted precision in an oral small molecule format is what makes icotrokinra mechanistically distinctive. It is not a large protein antibody requiring injection. It is a peptide that survives oral ingestion and reaches the target receptor after absorption from the gastrointestinal tract. The pharmacological challenge of engineering peptides that can do this reliably is substantial, which is why icotrokinra is the first of its kind to reach approval.

How icotrokinra compares to other oral psoriasis treatments Apremilast (Otezla) is an oral PDE4 inhibitor that broadly dampens inflammatory signaling. It produces IGA 0/1 rates of approximately 20 to 30% at 16 weeks and PASI 75 rates of approximately 40% in pivotal trials. It is generally considered a step below biologics in efficacy for moderate to severe disease. Deucravacitinib (Sotyktu) is an oral TYK2 inhibitor that selectively suppresses IL-23 and IL-12 signaling. In its pivotal POETYK PSO-1 and PSO-2 trials, it produced IGA 0/1 rates of 53 to 58% and PASI 75 rates of 58 to 65% at week 24, positioning it meaningfully above apremilast. Icotrokinra produced IGA 0/1 rates of 65 to 70% and PASI 90 rates of 50 to 57% at week 16 across its pivotal trials, with head-to-head superiority demonstrated directly against deucravacitinib in ICONIC-ADVANCE 1 and 2. No head-to-head trial comparing icotrokinra to IL-17 or IL-23 biologics has been completed. Where icotrokinra fits in the treatment hierarchy will be determined by payer formularies, prescriber experience, and individual patient considerations including injection hesitancy, comorbidities, and treatment history.

The ICONIC Clinical Development Program: What the Data Shows

The FDA approval is based on five Phase 3 randomized controlled trials collectively enrolling more than 2,500 patients, designated the ICONIC program. The co-primary endpoints across studies were the proportion of patients achieving IGA 0/1 (clear or almost clear skin) with at least a 2-grade improvement, and PASI 90 (at least 90% improvement in psoriasis severity from baseline), both at week 16.

ICONIC-ADVANCE 1 and 2: the pivotal approval studies with active comparator

The two pivotal trials supporting the approval are ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), published simultaneously in The Lancet in September 2025. These trials were randomized, double-blind, placebo-controlled and active-comparator-controlled, comparing icotrokinra (200 mg once daily) to both placebo and deucravacitinib (6 mg once daily) in adults with moderate to severe plaque psoriasis.

Endpoint at Week 16	Icotrokinra	Placebo	Deucravacitinib
IGA 0/1 (ADVANCE 1)	68% (213/311)	11% (17/156)	49%
IGA 0/1 (ADVANCE 2)	70% (227/322)	9% (7/82)	49%
PASI 90 (ADVANCE 1)	55% (171/311)	4% (6/156)	36%
PASI 90 (ADVANCE 2)	57% (184/322)	1% (1/82)	38%
PASI 100 complete clearance (ADVANCE 1, Week 16)	~33%	Less than 1%	~17%
PASI 100 complete clearance (ADVANCE 2, Week 16)	~33%	Less than 1%	~16%

Source: Gold et al. The Lancet. 2025. doi:10.1016/S0140-6736(25)01576-4.

Both coprimary endpoints and all key secondary endpoints were met in each study. Icotrokinra demonstrated statistically significant superiority over deucravacitinib on both IGA 0/1 and PASI 90 at week 16, with treatment differences of approximately 19 to 20 percentage points on IGA 0/1 and approximately 18 to 19 percentage points on PASI 90 versus deucravacitinib. This head-to-head superiority over the most recently approved oral systemic therapy is the most clinically significant efficacy finding in the dataset.

ICONIC-LEAD: adolescent and adult data

ICONIC-LEAD (NCT06095115) enrolled 684 participants (456 icotrokinra, 228 placebo) in a 2:1 randomization. This study evaluated both adults and adolescents and provides the specific data supporting the pediatric indication. At week 16, 65% of icotrokinra-treated patients achieved IGA 0/1 versus 8% with placebo (difference 56%; 95% CI 50 to 62%), and 50% achieved PASI 90 versus 4% with placebo (difference 45%; 95% CI 40 to 50%). By week 24, these rates improved to 74% IGA 0/1 and 65% PASI 90.

ICONIC-TOTAL: high-impact sites

ICONIC-TOTAL (NCT06095102) specifically enrolled patients with plaque psoriasis affecting high-impact and difficult-to-treat areas including scalp, genitals, and hands/feet. At 52 weeks, 72% of patients with scalp psoriasis achieved scalp-specific IGA 0/1 clearance. Genital and hand/foot clearance rates were similarly high. These difficult-to-treat locations are often where patients report the greatest impact on quality of life and where many existing systemic therapies show lower effectiveness than in non-special site disease.

52-week durability data

One-year data from ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD, presented at the 2026 American Academy of Dermatology Annual Meeting in March 2026, showed that response rates continued to improve beyond week 16. PASI 100 (completely clear skin) rates increased from 33 to 41% at week 24 to 48 to 49% at week 52 across the two ADVANCE studies. No new safety signals were identified through 52 weeks of treatment.

Safety Profile

Across the ICONIC clinical program, icotrokinra demonstrated what the FDA and independent reviewers characterized as a placebo-like safety profile at week 16, with adverse event rates within 1.1 percentage points of placebo. No new safety signals emerged through 52 weeks of follow-up.

Common adverse events reported in trials:

Headache
Nausea
Cough
Mild fungal infections (predominantly oral candidiasis)
Upper respiratory tract infection
Fatigue

Key safety considerations from the prescribing information:

Tuberculosis screening is required before initiating icotrokinra, consistent with other immunomodulating therapies. Live vaccines should not be administered during treatment. Providers should monitor for signs and symptoms of infection throughout the treatment course.

The absence of the elevated cardiovascular risk signals observed with some JAK inhibitors, and the absence of the hepatic or hematologic monitoring requirements associated with older systemic therapies like methotrexate, are practical clinical advantages in a patient population that often has cardiovascular comorbidities.

Dosing and Administration

Dose: 200 mg once daily
Timing: Upon waking, at least 30 minutes before eating
Method: One tablet swallowed with water. For patients who have difficulty swallowing tablets, the tablet may be dispersed in at least 120 mL of water; administration should be completed within 15 minutes of dispersion
Who is eligible: Adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy

Where Icotrokinra Fits in Psoriasis Treatment

Current treatment guidelines from the American Academy of Dermatology recommend a stepwise approach. Topical therapies are typically first-line for mild disease. Systemic therapy becomes appropriate when topical treatments fail or disease is classified as moderate to severe.

For systemic therapy, the options now include:

Conventional systemic agents: methotrexate, cyclosporine, acitretin. Effective but carry significant monitoring burdens and toxicity profiles
Apremilast (Otezla): oral PDE4 inhibitor. Modest efficacy, generally better tolerated than conventional systemic agents
Deucravacitinib (Sotyktu): oral TYK2 inhibitor. More effective than apremilast, now demonstrated to be less effective than icotrokinra on primary endpoints
Biologic therapies targeting IL-17 or IL-23: highest efficacy class but require injection (ixekizumab, secukinumab, guselkumab, risankizumab, bimekizumab, others)
Icotrokinra (ICOTYDE): oral IL-23R peptide. Efficacy on primary endpoints exceeds prior oral options and approaches biologic-level response rates in some analyses

Icotrokinra’s approval creates a new clinical decision point for prescribers who have patients with moderate to severe disease who prefer or require oral treatment but have not achieved adequate responses on apremilast or deucravacitinib, or who want to avoid injectable biologics.

Whether icotrokinra will move earlier in the treatment sequence, potentially as first-line systemic therapy, will depend on payer formulary decisions, prescriber adoption patterns, and the results of the ongoing ICONIC-ASCEND trial (NCT06934226), which compares icotrokinra to ustekinumab (an IL-12/23 biologic) and will provide the first direct head-to-head data versus an injectable biologic.

For Patients

If you have moderate to severe plaque psoriasis and are currently on a systemic therapy that is not achieving adequate control, or if you have been reluctant to try injectable biologics, icotrokinra adds a clinically meaningful new oral option to the conversation you can have with your dermatologist.

It is not a replacement for injectable biologics in patients who are doing well on those regimens. It is an alternative for patients for whom oral treatment is preferable, for whom prior oral therapies were insufficient, or who are appropriate candidates for first-line systemic therapy.

Patient support is available through Johnson & Johnson’s ICOTYDE withMe program, which provides cost assistance options and educational resources. Information on eligibility and enrollment is available at icotyde.com.

The National Psoriasis Foundation maintains current information on all approved psoriasis treatments, including patient perspectives, treatment decision support tools, and a healthcare provider directory for finding dermatologists with psoriasis expertise. The American Academy of Dermatology’s “Find a Dermatologist” tool is a reliable starting point for patients seeking specialist care.

For related coverage of first-in-class oral therapies across different conditions in 2026, see our post on Foundayo (orforglipron), the first non-peptide oral GLP-1 receptor agonist approved for weight management, which represents a parallel story of oral formulation innovation changing a treatment landscape previously dominated by injectables.

Sources

FDA approval announcement: FDA approves icotrokinra for moderate to severe plaque psoriasis. FDA.gov. March 18, 2026.

Johnson & Johnson approval press release: FDA Approval of ICOTYDE (icotrokinra) Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis. jnj.com. March 18, 2026.

ICONIC-ADVANCE 1 and 2 primary publication: Gold LS, Armstrong A, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. The Lancet. 2025. doi:10.1016/S0140-6736(25)01576-4.

ICONIC-LEAD 24-week data: Phase 3 Findings Suggest Icotrokinra Effective in Adults, Adolescents with Psoriasis. HCPLive. January 2026.

52-week data press release: ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile. PRNewswire. March 28, 2026.

ICONIC-TOTAL scalp/genital data: Icotrokinra long-term results affirm promise in difficult-to-treat scalp and genital psoriasis. JNJ Investor. October 2025.

Dermatology Times approval coverage: FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis. Dermatology Times. April 2026.

HMP Global approval summary: FDA Approves Icotyde for Moderate-to-Severe Plaque Psoriasis. HMP Global Learning Network. March 2026.

Rheumatology Advisor ICONIC-LEAD data: FDA Approves Oral Icotrokinra for Moderate to Severe Plaque Psoriasis. Rheumatology Advisor. March 2026.

ICONIC trial registrations: ICONIC-ADVANCE 1 (NCT06143878) | ICONIC-ADVANCE 2 (NCT06220604) | ICONIC-LEAD (NCT06095115) | ICONIC-TOTAL (NCT06095102)

Deucravacitinib FDA approval: FDA approves deucravacitinib for plaque psoriasis. FDA.gov.

Apremilast FDA approval: FDA approves apremilast for psoriatic arthritis. FDA.gov.

IL-23 pathway reference: IL-23 and psoriasis pathogenesis. PMC6429360.

Biologic therapy review: IL-17 and IL-23 pathway inhibition in psoriasis. PMC7460559.

Patient resources: National Psoriasis Foundation | AAD Find a Dermatologist | ICOTYDE patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about psoriasis treatment, including whether icotrokinra is appropriate for your situation, should be made in consultation with a board-certified dermatologist who can evaluate your individual disease characteristics, treatment history, and comorbidities.

April 10, 2026